Cefaclor

Authoritative Clinical Reference

DRUG NAME: Cefaclor

INN / USAN: Cefaclor (no difference between INN and USAN)

ℹ️ Cefaclor is available as the free base in immediate-release capsules and oral suspensions, and as cefaclor monohydrate in modified-release (CD/SR) tablet formulations. The monohydrate form is used specifically for the controlled-delivery matrix and is not dose-interchangeable with the immediate-release capsule on a milligram-for-milligram basis due to different release profiles. Dosing for each formulation type is addressed separately under Indications + Dosing.

Therapeutic Class

Antibiotic

Subclass

Second-generation cephalosporin (oral) — Beta-lactam antibiotic with enhanced Gram-negative activity compared to first-generation cephalosporins while retaining reasonable Gram-positive coverage.

Speciality

Primary Speciality: Infectious Disease
Also used in: ENT, Pulmonology, Paediatrics

Schedule (India)

Schedule H

All formulations of cefaclor (capsules, modified-release tablets, dry syrup for oral suspension) fall under Schedule H.
Requires a valid prescription for dispensing. No OTC status for any formulation.
Not classified under Schedule H1 (no additional record-keeping requirement for the pharmacist beyond standard Schedule H prescription retention).

Route(s)

Oral — Capsules, modified-release tablets, oral suspension (reconstituted dry syrup)

ℹ️ Cefaclor is available only as an oral formulation. No parenteral, topical, or inhaled forms exist.

Biosimilar Status

Not a biologic — biosimilar classification not applicable.

Cefaclor is a small-molecule chemical antibiotic. Standard generic pharmaceutical equivalence and bioequivalence apply.

Formulations Available in India

Single-Ingredient Formulations

Dosage Form	Available Strengths	Notes
Capsules (immediate-release)	250 mg, 500 mg	Most widely available formulation in India
Modified-release tablets (Cefaclor CD / SR)	375 mg, 500 mg	Contains cefaclor monohydrate in controlled-delivery matrix; not interchangeable with IR capsules; limited availability in India
Dry syrup for oral suspension	125 mg/5 mL, 250 mg/5 mL (reconstituted)	Available in 30 mL and 60 mL bottles; primary paediatric formulation
Oral drops	25 mg/drop or 50 mg/mL	Limited availability; intended for infants; verify brand-specific concentration before use

Fixed-Dose Combinations (FDCs) Available in India

ℹ️ No commonly prescribed or CDSCO-approved FDCs containing cefaclor are in widespread clinical use in India. Cefaclor is predominantly prescribed as a single-ingredient formulation.

⛔ No FDC of cefaclor has been specifically banned by CDSCO as of the date of this monograph. However, prescribers should verify the CDSCO FDC ban list (updated periodically) before prescribing any combination product.

PHARMACOKINETICS

Primary Pharmacokinetic Parameters

Parameter	Immediate-Release (Capsule / Suspension)	Modified-Release (CD Tablet)
Bioavailability (oral)	~93–95%; well absorbed from GI tract	~77–83% (lower peak but more sustained levels)
T_max	0.5–1 hour (capsule); 1 hour (suspension — slightly faster than capsule)	1.5–2.5 hours
Protein binding	~22–25% (primarily to albumin)	Same
Volume of distribution (Vd)	~0.24–0.35 L/kg	Same
Metabolism	Partially metabolised in the liver; not via CYP450 enzymes to any clinically significant extent; no clinically active metabolites	Same
Half-life (t½)	0.6–0.9 hours (~36–54 minutes) — notably short among oral cephalosporins; prolonged in severe renal impairment (up to 2.3–2.8 hours when CrCl <10 mL/min)	~1.0–1.5 hours (apparent prolongation due to sustained absorption, not true elimination difference)
Excretion	Primarily renal: ~60–85% excreted unchanged in urine within 8 hours via glomerular filtration and tubular secretion; small fraction excreted in faeces via bile	Same renal excretion pathway
Dialysability	Partially removed by haemodialysis (~55% removed in a 4-hour session); poorly removed by peritoneal dialysis	Same
Food effect	Food delays T_max by ~0.5–0.75 hours and may reduce C_max by ~50%, but total absorption (AUC) is not significantly reduced. Can be taken with or without food; however, taking with food may reduce GI side effects.	Must be taken with food — food significantly improves bioavailability and is required for proper controlled-release matrix function
Onset of action	Clinical onset: ~30–60 minutes; bactericidal activity begins as serum levels exceed MIC of target pathogens	Slightly delayed onset (~1–2 hours) due to controlled release
Duration of action	~8 hours (standard TDS dosing maintains adequate MIC coverage for susceptible organisms)	~12 hours (allows BD dosing)

Drug Transporter Profile

Transporter	Role
PEPT1 (Peptide transporter 1)	Cefaclor is a substrate of the intestinal PEPT1 transporter, which facilitates its high oral absorption — similar to other aminocephalosporins
P-glycoprotein (P-gp)	Not a clinically significant substrate, inhibitor, or inducer
OAT1/OAT3 (Organic anion transporters)	Substrate of renal OATs — contributes to active tubular secretion; probenecid inhibits this pathway and increases cefaclor levels
OATP1B1/1B3, BCRP, OCT2, MATE1/2	Not clinically significant substrates, inhibitors, or inducers

Prodrug Status

Cefaclor is NOT a prodrug. It is administered as the active compound and does not require metabolic activation.

Non-Linear Pharmacokinetics

No clinically significant non-linear pharmacokinetics. Absorption and elimination follow linear kinetics within the therapeutic dose range (250–500 mg).

Population PK Notes

Population	PK Consideration
Elderly (≥60 years)	Reduced renal function with age leads to modestly prolonged half-life (~1.0–1.5 hours with age-appropriate CrCl decline). Dose adjustment based on renal function rather than age per se.
Paediatric	Half-life in neonates (especially preterm) may be prolonged (up to 2–3 hours) due to immature renal function. In children >1 year, PK is broadly similar to adults on a weight-adjusted basis. Higher weight-normalised clearance in children 1–12 years may necessitate dosing at upper end of mg/kg range.
Obesity	No well-documented clinically significant alteration in Vd or clearance requiring dose adjustment. Standard dosing is generally adequate for moderately obese patients. For severely obese patients (BMI >40), data is limited.
Pregnancy	Limited formal PK data. General cephalosporin class data suggests increased renal clearance in pregnancy (particularly second and third trimester), potentially leading to lower serum levels. Clinical significance for cefaclor specifically is not well established.
Critical illness / ICU patients	Data limited for cefaclor specifically. Augmented renal clearance (ARC) in younger, non-elderly ICU patients could lead to subtherapeutic levels, but cefaclor is rarely the antibiotic of choice in ICU settings.
Renal impairment	Half-life prolonged significantly: ~2.3–2.8 hours when CrCl <10 mL/min (compared to ~0.6–0.9 hours normally). Dose adjustment recommended. See Renal Adjustment section.
Hepatic impairment	Hepatic metabolism is a minor elimination pathway. No clinically significant PK changes expected in hepatic impairment. No dose adjustment required.

Key PK-Guided Clinical Notes

💡 Short half-life implication: The short half-life (~0.6–0.9 hours) means cefaclor relies on time above MIC (T > MIC) for bactericidal efficacy, consistent with all beta-lactam antibiotics. This mandates TDS (three times daily) dosing for the immediate-release formulation to maintain adequate serum levels above the MIC throughout the dosing interval. The modified-release formulation extends this to BD dosing.

💡 Probenecid interaction (PK basis): Probenecid competitively inhibits renal tubular secretion of cefaclor via OAT transporters, increasing cefaclor serum levels by ~40–50% and prolonging the half-life. This interaction was historically used therapeutically but is not routinely recommended in current Indian practice.

💡 Suspension vs Capsule bioequivalence: The oral suspension produces a slightly faster T_max but equivalent total absorption (AUC) compared to capsules. The two formulations are considered bioequivalent for clinical purposes.

ADULT INDICATIONS + DOSING

⚠️ Antimicrobial Stewardship Reminder: Cefaclor is a second-generation cephalosporin. Before prescribing, consider whether a narrower-spectrum agent (e.g., amoxicillin) or no antibiotic at all is appropriate. Use culture and sensitivity data when available. Avoid empirical broad-spectrum use where a targeted agent would suffice.

ℹ️ NLEM Status: Cefaclor is NOT included in the current NLEM India (2022 edition). Among oral cephalosporins, cephalexin (1st generation) and cefixime (3rd generation) are included in the NLEM. This does not preclude cefaclor’s use but may affect cost-effectiveness considerations and government supply availability.

ℹ️ Formulation-Specific Dosing Alert: The immediate-release (IR) capsules and the modified-release (CD/SR) tablets have different dosing schedules, bioavailability profiles, and food requirements. They are NOT interchangeable on a milligram-for-milligram basis. Dosing for each is specified separately throughout this section.

Antimicrobial Spectrum — Quick Reference

Before dosing, the prescriber must consider the drug’s spectrum of activity:

Coverage	Key Organisms
Gram-positive	Streptococcus pyogenes (Group A), S. pneumoniae (penicillin-susceptible), Staphylococcus aureus (MSSA only — not MRSA)
Gram-negative	Haemophilus influenzae (including many beta-lactamase producers), Moraxella catarrhalis, Escherichia coli (many strains), Klebsiella pneumoniae (many strains), Proteus mirabilis
NOT active against	⛔ MRSA, ⛔ Pseudomonas aeruginosa, ⛔ Enterococcus spp., ⛔ Enterobacter spp., ⛔ Anaerobes (weak to nil activity against Bacteroides fragilis), ⛔ Atypical pathogens (Mycoplasma, Chlamydophila, Legionella)

⚠️ Rising resistance note: Indian surveillance data (ICMR AMR surveillance network) shows increasing resistance among common uropathogens (E. coli, Klebsiella) to second-generation cephalosporins. Always consider local antibiogram data when treating UTIs empirically.

Primary Indications (Approved / Standard in India) — Adults

1. Upper Respiratory Tract Infections (URTI) — Acute Bacterial Pharyngitis / Tonsillitis, Acute Bacterial Sinusitis, Acute Otitis Media

ℹ️ These three conditions are grouped because cefaclor dosing is broadly similar across them. Condition-specific notes are provided separately below the dosing table.

Dosing Table

Formulation	Starting Dose	Titration	Usual Maintenance Dose	Maximum Dose	Duration	Clinical Notes
IR Capsule	250 mg TDS (every 8 hours)	Increase to 500 mg TDS if severe infection or poor initial response	250 mg TDS (mild–moderate); 500 mg TDS (severe)	Max 500 mg per dose; Max 1500 mg per day (standard)	See condition-specific notes below	Take with or without food; food delays absorption but does not reduce total absorption
CD/SR Tablet	375 mg BD (every 12 hours)	Increase to 500 mg BD if needed	375 mg BD (mild–moderate); 500 mg BD (moderate–severe)	Max 500 mg per dose; Max 1000 mg per day	See condition-specific notes below	⚠️ Must be taken with food for proper release
Oral Suspension	250 mg (10 mL of 125 mg/5 mL, or 5 mL of 250 mg/5 mL) TDS	As for capsule	As for capsule	As for capsule	As for capsule	Used in adults who cannot swallow capsules

Condition-Specific Notes

A. Acute Bacterial Pharyngitis / Tonsillitis (Streptococcal)

Duration: 10 days (to ensure Group A Streptococcal eradication and prevent rheumatic fever — this is non-negotiable; shorter courses are inadequate for GAS pharyngitis)
When to prefer cefaclor: Consider in patients with penicillin allergy (non-anaphylactic type — delayed rash, GI intolerance to amoxicillin) where oral cephalosporins are deemed safe. Also reasonable when H. influenzae co-infection is suspected (e.g., concurrent sinusitis).
When NOT to use: ⛔ Do not use in patients with history of immediate/anaphylactic-type penicillin allergy (urticaria, angioedema, bronchospasm, anaphylaxis) — cross-reactivity risk with cephalosporins is ~1–2%, and in this scenario, prefer azithromycin or clindamycin instead. Also, do not use for viral pharyngitis — confirm bacterial aetiology via clinical criteria (Centor/McIsaac score ≥3) or rapid antigen test/culture.
Preferred alternatives in India: Amoxicillin (500 mg TDS × 10 days) is the first-line drug for GAS pharyngitis (API Textbook of Medicine, ICMR guidelines). Cefaclor is a second-line option. Phenoxymethylpenicillin (Penicillin V) remains effective but is less commonly available/used in India.
NLEM status for this indication: Not applicable — cefaclor is not in NLEM. Amoxicillin (the preferred drug) is in NLEM.
Time to expected clinical response: Fever and throat pain typically improve within 48–72 hours. Failure to improve by 72 hours warrants reassessment.
Treatment failure criteria: Persistent fever, worsening symptoms, or recurrence within 2 weeks → consider culture, assess compliance, switch to amoxicillin-clavulanate or azithromycin.
Mandatory baseline investigations: None mandatory for uncomplicated pharyngitis. Throat culture or rapid antigen detection test (RADT) is recommended if available — especially in children and young adults at risk of rheumatic fever (still highly prevalent in India).
Specialist initiation: Not required. Appropriate for primary care / PHC prescribing.
Indian guideline source: API Textbook of Medicine (relevant chapter on Streptococcal infections); ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes (2019 edition).
Key safety warning: ⚠️ In India, rheumatic fever and rheumatic heart disease remain significant. Incomplete treatment of GAS pharyngitis is a major risk factor. Always emphasise full 10-day course completion.
Dose adjustment scenarios: Renal impairment — see Renal Adjustment section.

B. Acute Bacterial Sinusitis

Duration: 10–14 days (standard); 5–7 days may be considered for mild cases with clear clinical response.
When to prefer cefaclor: Second-line option when amoxicillin or amoxicillin-clavulanate is not tolerated. Cefaclor provides coverage against H. influenzae and M. catarrhalis — the two most common beta-lactamase-producing sinusitis pathogens.
When NOT to use: Chronic sinusitis (often polymicrobial including anaerobes — cefaclor has poor anaerobic coverage); complicated sinusitis (orbital/intracranial extension); suspected fungal sinusitis.
Preferred alternatives in India: Amoxicillin-clavulanate (first-line for ABRS per Indian ENT practice and API Textbook). For penicillin-allergic patients: cefaclor or cefuroxime (oral) are reasonable options.
Time to expected clinical response: 48–72 hours. If no improvement by day 3, reassess diagnosis and consider imaging (CT sinuses) and switch to amoxicillin-clavulanate or doxycycline + metronidazole.
Treatment failure criteria: Persistent symptoms beyond 72 hours, worsening facial pain/fever, or development of complications → switch antibiotic and consider ENT referral.
Mandatory baseline investigations: None mandatory. CT sinuses is recommended if chronic or complicated disease is suspected — not for uncomplicated acute sinusitis.
Specialist initiation: Not required for acute uncomplicated sinusitis. ENT referral recommended for chronic, recurrent, or complicated sinusitis.

C. Acute Otitis Media (AOM)

Duration: 7–10 days (standard for adults; 5–7 days may be adequate for mild cases in otherwise healthy adults).
When to prefer cefaclor: When amoxicillin has failed or is not tolerated. Provides better coverage of beta-lactamase-producing H. influenzae than amoxicillin alone.
When NOT to use: Complicated AOM (mastoiditis, intracranial complications); chronic suppurative otitis media (CSOM) — requires different antibiotic approach and often topical ear drops ± systemic antibiotics with anti-pseudomonal or anaerobic coverage.
Preferred alternatives in India: Amoxicillin (first-line); amoxicillin-clavulanate (first-line if beta-lactamase-producing organism suspected); cefuroxime axetil (alternative oral cephalosporin).
Time to expected clinical response: 48–72 hours.
Specialist initiation: Not required for uncomplicated AOM. ENT referral for recurrent AOM (≥3 episodes in 6 months), treatment failure, or complications.

2. Lower Respiratory Tract Infections (LRTI) — Acute Bronchitis, Acute Exacerbation of Chronic Bronchitis (AECB), Mild Community-Acquired Pneumonia (CAP)

Dosing Table

Formulation	Starting Dose	Titration	Usual Maintenance Dose	Maximum Dose	Duration	Clinical Notes
IR Capsule	250 mg TDS	Increase to 500 mg TDS for moderate–severe infection	250–500 mg TDS	Max 500 mg per dose; Max 1500 mg per day	See condition-specific notes	—
CD/SR Tablet	500 mg BD	Not applicable (start at the higher dose for LRTI)	500 mg BD	Max 500 mg per dose; Max 1000 mg per day	See condition-specific notes	Must be taken with food

Condition-Specific Notes

A. Acute Bronchitis

⚠️ Most cases of acute bronchitis are viral and DO NOT require antibiotics. Antibiotics are recommended ONLY when bacterial superinfection is suspected (purulent sputum >7–10 days, high fever, declining clinical trajectory, patient with underlying COPD/immunosuppression).
Duration: 5–7 days (if antibiotics are indicated).
Preferred alternatives in India: Amoxicillin or doxycycline are commonly used first-line. Cefaclor is a second-line option.
Time to expected clinical response: 48–72 hours. Cough may persist for 2–3 weeks even after successful bacterial clearance.
NLEM status: Not applicable.
Specialist initiation: Not required. Appropriate for primary care.

B. Acute Exacerbation of Chronic Bronchitis (AECB) / AECOPD

Duration: 5–7 days.
When to prefer cefaclor: When an oral cephalosporin is desired and amoxicillin-clavulanate is not tolerated. Provides coverage against H. influenzae and M. catarrhalis — key AECB pathogens.
When NOT to use: Severe AECOPD requiring hospitalisation (parenteral antibiotics preferred — ceftriaxone, piperacillin-tazobactam); suspected Pseudomonas colonisation (common in severe COPD with frequent exacerbations and bronchiectasis) — cefaclor has no Pseudomonas coverage.
Preferred alternatives in India: Amoxicillin-clavulanate (first-line per Indian Chest Society / GOLD guidelines adapted for India); doxycycline; azithromycin.
Anthonisen criteria for antibiotic use in AECB: Antibiotics are recommended when ≥2 of: increased dyspnoea, increased sputum volume, increased sputum purulence. If only 1 criterion present, antibiotics are generally not needed.
Indian guideline source: Indian Chest Society guidelines for COPD management; API Textbook of Medicine (chapter on COPD).
Time to expected clinical response: 48–72 hours.
Treatment failure criteria: Worsening dyspnoea, persistent purulent sputum, fever — reassess, obtain sputum culture, and consider switching to amoxicillin-clavulanate or a fluoroquinolone (levofloxacin/moxifloxacin) or parenteral antibiotics.
Specialist initiation: Not required for outpatient AECB. Pulmonology referral for frequent exacerbators (≥2 per year).

C. Mild Community-Acquired Pneumonia (CAP) — Outpatient Management

⚠️ Cefaclor has significant limitations for CAP: It does NOT cover atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila), which account for a significant proportion of CAP in younger adults. Therefore, cefaclor as monotherapy is suboptimal for CAP in most clinical scenarios.
Duration: 5–7 days (minimum 5 days; patient should be afebrile for ≥48 hours before stopping).
When to prefer cefaclor: Very limited role. May be considered ONLY for mild CAP in elderly patients where S. pneumoniae or H. influenzae is the most likely pathogen and atypical coverage is not a priority (e.g., CURB-65 score 0–1, no atypical features). Even here, amoxicillin ± macrolide is preferred.
When NOT to use: Moderate-to-severe CAP (CURB-65 ≥2); suspected atypical pneumonia (age <40, non-productive cough, extrapulmonary features); aspiration pneumonia (anaerobic coverage needed); hospital-acquired pneumonia.
Preferred alternatives in India:
- ICMR/Indian guidelines: Amoxicillin ± azithromycin (for outpatient mild CAP) OR amoxicillin-clavulanate + azithromycin/doxycycline.
- Respiratory fluoroquinolones (levofloxacin, moxifloxacin) — for penicillin-allergic patients or treatment failure, but fluoroquinolone stewardship is encouraged.
Mandatory baseline investigations: Chest X-ray (recommended). Sputum Gram stain and culture if available. SpO₂ assessment.
Treatment failure criteria: No improvement or worsening within 48–72 hours → obtain chest X-ray, sputum culture, blood cultures; consider hospitalisation and parenteral antibiotics.
Indian guideline source: ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes (2019); Indian Chest Society/NCCP CAP guidelines.
Specialist initiation: Not required for mild outpatient CAP. Pulmonology/Infectious Disease referral for treatment failure or complicated pneumonia.

3. Uncomplicated Urinary Tract Infections (UTI) — Acute Cystitis

Dosing Table

Formulation	Starting Dose	Titration	Usual Maintenance Dose	Maximum Dose	Duration	Clinical Notes
IR Capsule	250 mg TDS	Not applicable for uncomplicated cystitis	250 mg TDS	Max 500 mg per dose; Max 1500 mg per day	7 days (standard); 3-day course may be considered for uncomplicated cystitis in young women with mild symptoms	—
CD/SR Tablet	375 mg BD	Not applicable	375 mg BD	Max 500 mg per dose; Max 1000 mg per day	7 days	Must be taken with food

Mandatory Clinical Notes

When to prefer cefaclor: Very limited first-line role in current Indian practice given rising cephalosporin resistance among uropathogens. Consider ONLY when culture shows susceptibility and first-line agents are not tolerable.
When NOT to use: ⛔ Complicated UTI, pyelonephritis (except very mild, confirmed susceptible — and even then, first-generation cephalosporins or amoxicillin-clavulanate are preferred), catheter-associated UTI, UTI in men (usually complicated by definition).
⚠️ Indian resistance context: ICMR AMR surveillance data consistently shows high rates of E. coli resistance to cephalosporins in Indian community isolates (often >40–60% in some regions due to ESBL production). Cefaclor should NOT be used empirically for UTI in India without culture-sensitivity data unless local antibiogram supports it.
Preferred alternatives in India for uncomplicated cystitis:
- First-line: Nitrofurantoin 100 mg BD × 5 days (ICMR-recommended; best resistance profile)
- Alternative: Fosfomycin 3 g single dose (oral)
- Avoid fluoroquinolones for uncomplicated cystitis (stewardship concern)
NLEM status: Not applicable.
Mandatory baseline investigations: Urine routine and microscopy (recommended). Urine culture and sensitivity (recommended in India given high resistance rates; mandatory in recurrent UTI, treatment failure, or complicated UTI).
Time to expected clinical response: Symptom improvement within 24–48 hours. Dysuria should resolve by day 3.
Treatment failure criteria: Persistent or worsening symptoms at 48–72 hours → obtain urine culture if not already sent; switch antibiotic based on sensitivity.
Specialist initiation: Not required. Appropriate for primary care. Urology/Nephrology referral for recurrent UTI (≥3 per year), complicated UTI, or structural abnormalities.
Indian guideline source: ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes (2019); API Textbook of Medicine (chapter on UTI).
Key safety warning: ⚠️ Avoid using cefaclor empirically for UTI in India unless local antibiogram supports susceptibility. Empirical cephalosporin use contributes to ESBL selection pressure.

4. Skin and Soft Tissue Infections (SSTIs) — Uncomplicated

Dosing Table

Formulation	Starting Dose	Titration	Usual Maintenance Dose	Maximum Dose	Duration	Clinical Notes
IR Capsule	250 mg TDS	Increase to 500 mg TDS for moderate infections	250 mg TDS (mild); 500 mg TDS (moderate)	Max 500 mg per dose; Max 1500 mg per day	7–10 days	—
CD/SR Tablet	375 mg BD	Increase to 500 mg BD if needed	375–500 mg BD	Max 500 mg per dose; Max 1000 mg per day	7–10 days	Must be taken with food

Mandatory Clinical Notes

When to prefer cefaclor: Uncomplicated skin infections (impetigo, cellulitis, wound infections) caused by susceptible S. aureus (MSSA) or Streptococcus pyogenes. Reasonable option when amoxicillin-clavulanate is not tolerated.
When NOT to use: ⛔ Suspected or confirmed MRSA infection (cefaclor has NO MRSA activity — prevalence of community-acquired MRSA in India varies by region but is significant in many urban centres). ⛔ Deep-seated infections (necrotising fasciitis, osteomyelitis, septic arthritis). ⛔ Animal/human bite wounds (require anaerobic coverage — amoxicillin-clavulanate preferred). ⛔ Diabetic foot infections (usually polymicrobial including anaerobes and Gram-negatives resistant to cefaclor).
Preferred alternatives in India:
- MSSA skin infections: Cephalexin (first-generation — narrower spectrum, preferred per antimicrobial stewardship), cloxacillin/dicloxacillin, amoxicillin-clavulanate.
- Suspected MRSA: Cotrimoxazole, doxycycline, clindamycin, linezolid (based on severity).
NLEM status: Not applicable.
Time to expected clinical response: Erythema and swelling should begin improving within 48–72 hours. Mark the borders of cellulitis to track progression/regression.
Treatment failure criteria: Expanding erythema, persistent fever, development of fluctuance or crepitus at 48–72 hours → reassess; consider incision and drainage if abscess; switch antibiotic (add MRSA coverage); obtain wound culture.
Mandatory baseline investigations: None mandatory for uncomplicated SSTI. Wound culture (recommended if abscess present, recurrent infection, or treatment failure). Blood cultures if systemic toxicity present (but such patients usually need parenteral antibiotics, not cefaclor).
Specialist initiation: Not required for uncomplicated SSTI. Surgical referral for abscess drainage. Infectious Disease referral for deep-seated or non-resolving infections.
Indian guideline source: API Textbook of Medicine; IADVL (Indian Association of Dermatologists, Venereologists and Leprologists) guidelines for bacterial skin infections.
Key safety warning: ⚠️ India has a high prevalence of community-acquired MRSA (CA-MRSA). Do not assume S. aureus SSTI will respond to cephalosporins without culture confirmation in areas of high MRSA prevalence.

Secondary Indications — Adults Only (Off-Label)

1. Prophylaxis for Recurrent Uncomplicated UTI in Women

Status: OFF-LABEL
Dose: 250 mg once at bedtime (continuous low-dose prophylaxis) for 6–12 months
Maximum dose: Max 250 mg per dose; Max 250 mg per day (prophylactic dosing)
Duration: 6–12 months, then reassess need
Specialist only: Recommended — Urology or Gynaecology oversight preferred
Evidence basis: Limited. Small observational studies and expert consensus support low-dose cephalosporin prophylaxis for recurrent UTI. Not based on large RCTs specific to cefaclor.
Level of evidence quality:Weak — Case series, expert opinion, and extrapolation from other cephalosporins.
Preferred alternatives: Nitrofurantoin 50–100 mg at bedtime (preferred first-line for UTI prophylaxis in India per ICMR guidelines — superior evidence and resistance profile); cotrimoxazole 240 mg at bedtime (alternative).
Clinical note: ⚠️ Long-term cephalosporin use for UTI prophylaxis is not recommended as a routine practice in India due to antimicrobial resistance concerns (ESBL selection pressure). Reserve for patients in whom nitrofurantoin and cotrimoxazole are contraindicated or not tolerated. Periodic urine culture (every 3–6 months) recommended during prophylaxis.

2. Step-Down Oral Therapy after Parenteral Cephalosporins

Status: OFF-LABEL but accepted standard practice in India (antibiotic step-down / IV-to-oral switch therapy)
Dose: 500 mg TDS (IR capsule)
Maximum dose: Max 500 mg per dose; Max 1500 mg per day
Duration: To complete total antibiotic course (usually 7–14 days total including parenteral phase)
Specialist only: Should be guided by the treating physician managing the infection
Evidence basis: Principle of IV-to-oral step-down therapy is well established. Cefaclor is one option when the isolate is confirmed susceptible and the patient is clinically improving, tolerating oral intake, and afebrile for ≥24–48 hours. However, more commonly used oral step-down agents include amoxicillin-clavulanate, cefixime, or cefpodoxime.
Level of evidence quality:Moderate — Well-established clinical principle; specific data for cefaclor in this role is limited compared to cefixime/cefpodoxime.
Clinical note: Always confirm sensitivity to cefaclor before switching. Ensure organism is susceptible and not an ESBL producer (ESBLs are resistant to all standard cephalosporins including cefaclor).

ℹ️ No other well-documented secondary (off-label) adult indications for cefaclor were identified with sufficient evidence to include in this formulary.

MISSED DOSE / DELAYED DOSE GUIDANCE

Immediate-Release Capsules / Oral Suspension (Three Times Daily — TDS Dosing)

Scenario	Action
Dose missed by <3 hours	Take the missed dose immediately. Adjust remaining doses to maintain approximately equal intervals for the rest of the day. Resume normal schedule the next day.
Dose missed by 3–6 hours	Take the missed dose. Skip the next dose if it would fall within 3 hours of the late dose. Do not double up. Resume normal schedule at the next scheduled time.
Dose missed by >6 hours	Skip the missed dose entirely. Take the next dose at the regular scheduled time. Do not take a double dose.

Modified-Release (CD/SR) Tablets (Twice Daily — BD Dosing)

Scenario	Action
Dose missed by <6 hours	Take the missed dose immediately with food. Take the next dose at the regular scheduled time if ≥6 hours away.
Dose missed by >6 hours	Skip the missed dose. Take the next dose at the regular scheduled time with food. Do not double up.

PRN Use

Not applicable — cefaclor is not a PRN medication.

Prolonged Non-Adherence / Drug Holiday Guidance

If ≥2 consecutive doses are missed: The antibiotic course may become subtherapeutic, increasing the risk of treatment failure and resistance development. Contact the prescriber to assess whether:
- The remaining course should be extended by the number of missed days
- A switch to an alternative antibiotic is warranted (especially if symptoms have worsened)
No re-titration is needed: Cefaclor can be resumed at the same dose without dose escalation.
No rebound effect: Cefaclor carries no risk of rebound or withdrawal effects upon sudden discontinuation or resumption.
⚠️ Key message to patients: Completing the full antibiotic course is essential. Do not stop early even if symptoms improve.

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

ℹ️ Cefaclor is an oral-only drug. No parenteral formulation exists. This section addresses reconstitution of the dry syrup for oral suspension and administration notes for all oral forms.

Reconstitution of Dry Syrup for Oral Suspension

Parameter	Details
Diluent	Freshly boiled and cooled drinking water (potable water)
Volume of diluent	As marked on the bottle label (varies by manufacturer and bottle size — typically to the marked line on the bottle for 30 mL or 60 mL reconstituted volume)
Procedure	1. Tap the bottle to loosen powder. 2. Add approximately half the required water. 3. Shake vigorously until powder is completely suspended. 4. Add remaining water to the mark on the bottle. 5. Shake again.
Final concentration	125 mg/5 mL or 250 mg/5 mL (as labelled)
Stability after reconstitution	14 days when stored in refrigerator (2–8°C). 7 days at room temperature (≤25°C). Discard any remaining suspension after 14 days regardless of storage conditions.
Storage	Refrigeration (2–8°C) preferred after reconstitution. If refrigeration not available (common in Indian PHC settings), keep in the coolest available area away from direct sunlight and use within 7 days.
Shake before each use	⚠️ YES — shake well before every dose to ensure uniform drug distribution. Settling occurs rapidly.

Oral Administration Notes

Formulation	Administration Instructions
IR Capsules (250 mg, 500 mg)	Swallow whole with a full glass of water. Can be taken with or without food. Taking with food may reduce GI side effects but delays absorption. Do NOT crush or open capsules.
CD/SR Tablets (375 mg, 500 mg)	⚠️ Swallow whole — do NOT crush, chew, split, or break. The modified-release matrix will be destroyed, leading to dose dumping. ⚠️ Must be taken with food — bioavailability is significantly reduced without food and the controlled-release mechanism requires food for proper function.
Oral Suspension	Use the measuring cup/spoon/oral syringe provided. Do not use household teaspoons (inaccurate dosing). Shake well before each use. May be mixed with a small amount of milk or fruit juice immediately before administration if the child or patient has difficulty with taste — but administer immediately after mixing; do not store the mixture.
Enteral (NG/PEG) tube	The oral suspension can be administered via nasogastric or PEG tube. Flush tube with 15–30 mL of water before and after administration. Do not crush IR capsules or CD/SR tablets for enteral administration — use the suspension formulation only.

Cold-Chain Drug Guidance

Before reconstitution: Store dry powder at room temperature (below 30°C), protected from moisture. No cold-chain required for the dry powder.
After reconstitution: Refrigeration (2–8°C) recommended. See stability table above.
ℹ️ In hot Indian climates (>35°C), if refrigeration is unavailable, reconstituted suspension should be used within 7 days. Counsel caregiver to store in the coolest part of the home (e.g., earthen pot, shaded area).

Other Sections (Not Applicable for Oral-Only Drug)

Section	Status
IV/IM reconstitution and dilution	Not applicable
Rate of administration	Not applicable
Weight-based IV dosing calculation	Not applicable
Y-site / Line compatibility	Not applicable
Filter requirements	Not applicable
Extravasation risk	Not applicable
Multi-dose vial handling	Not applicable

PAEDIATRIC DOSING (Specialist Only)

⚠️ Antimicrobial Stewardship Reminder: All paediatric antibiotic prescriptions should follow antimicrobial stewardship principles. Confirm bacterial aetiology before initiating antibiotics where feasible. Viral infections remain the predominant cause of respiratory illness in children.

ℹ️ NLEM / WHO EML Status: Cefaclor is NOT included in the current NLEM India (2022) or WHO EML for Children. Among oral cephalosporins for paediatric use, cephalexin (1st generation) and cefixime (3rd generation) are more commonly recommended in Indian guidelines. Cefaclor remains a valid second-line option when these agents are not tolerated or when susceptibility data supports its use.

General Notes

Safety Monitoring Requirements Specific to Paediatric Use

Monitor for GI tolerance — diarrhoea is the most common adverse effect in children and can lead to dehydration in young infants. Advise caregivers on oral rehydration if loose stools develop.
Monitor for allergic reactions — urticaria, maculopapular rash, pruritus, angioedema. Report immediately if any rash develops.
Monitor for superinfection — oral candidiasis (thrush), vulvovaginal candidiasis in older girls — particularly with courses >7 days. Treat with topical antifungals if it develops.
⚠️ Serum sickness-like reaction (SSLR): Cefaclor has a uniquely higher incidence of SSLR in children compared to other cephalosporins (~0.02–0.5% per course, higher with repeated courses — up to 0.5–2% with second or subsequent courses in some paediatric series). Characterised by erythema multiforme–like or urticarial rash, arthralgia/arthritis, and fever, typically occurring 7–21 days after starting therapy. This is NOT a true IgE-mediated allergy but a hypersensitivity reaction likely related to reactive cefaclor metabolite (delta-3 intermediate) formation. See dedicated SSLR management box below.
For prolonged courses (>14 days — uncommon for cefaclor): consider periodic CBC and renal function.
No routine blood monitoring required for standard short courses (≤14 days) in children with normal baseline organ function.

⚠️ Serum Sickness-Like Reaction (SSLR) — Paediatric-Specific Warning & Management

Parameter	Details
Incidence	~0.02–0.5% per treatment course; increases significantly with repeated courses (up to 0.5–2% on second/third course in some series)
Typical onset	7–21 days after starting therapy (may occur during or shortly after completing the course)
Presentation	Erythema multiforme–like or urticarial rash + arthralgia/joint swelling + fever. May include facial/periorbital oedema. Often misdiagnosed as drug allergy or acute rheumatic fever.
Mechanism	NOT IgE-mediated (not true anaphylaxis). Type III–like hypersensitivity to reactive cefaclor metabolites. Genetically susceptible individuals (possibly HLA-linked) at higher risk.
Management	1. Discontinue cefaclor immediately. 2. Oral antihistamines (cetirizine age-appropriate dose, or hydroxyzine). 3. Short course of oral prednisolone (1 mg/kg/day × 3–5 days) for moderate-severe cases (significant joint swelling or extensive rash). 4. Symptoms typically resolve within 2–5 days of discontinuation.
Recurrence risk	⛔ Do NOT re-challenge with cefaclor. Document the reaction in the patient’s records as “Cefaclor — SSLR.” Cross-reactivity with other cephalosporins is uncertain but generally low — other oral cephalosporins (cephalexin, cefuroxime, cefixime) can usually be used safely after SSLR to cefaclor, though caution is advised.
Counselling point	Inform parents/caregivers before starting therapy: “If your child develops a rash with joint pain and/or fever during or within 3 weeks of taking this medicine, stop the medicine and consult your doctor immediately.”

💡 Clinical Pearl [Evidence-based]: SSLR with cefaclor is a well-documented phenomenon unique to this drug’s metabolic profile. If a child needs multiple antibiotic courses over a season (e.g., recurrent AOM), consider rotating to a different class or using amoxicillin-clavulanate rather than repeated cefaclor courses to minimise SSLR risk.

ℹ️ Full discussion of SSLR also appears under Serious Adverse Effects (Part 4). The management box above is placed here for immediate clinical reference during paediatric prescribing decisions.

Minimum Age and Weight Limits

Parameter	Value
Minimum age (IR formulations)	1 month (use in neonates <1 month is limited — see neonatal section below)
Minimum age (CD/SR tablets)	Not recommended in children <12 years — CD/SR tablets are designed for adult dosing and must be swallowed whole; no paediatric dose titration possible; no paediatric PK data for the MR formulation
Minimum weight	No strict minimum weight cutoff; dose by mg/kg. Ensure accurate weighing before prescribing. For very low-weight infants (<5 kg), use oral drops (where available) for precise small-volume dosing.

Formulation Suitability for Children

Formulation	Suitability	Notes
Oral suspension (125 mg/5 mL, 250 mg/5 mL)	✅ Primary paediatric formulation	Available in India. Suitable from 1 month of age. Available in 30 mL and 60 mL bottles.
Oral drops (50 mg/mL)	✅ Suitable for infants	Allows precise small-volume dosing for infants <10 kg. Limited brand availability in India — verify concentration is as labelled before dispensing (some brands may use different concentrations).
IR Capsules (250 mg, 500 mg)	✅ For children who can swallow capsules whole	Generally suitable for children ≥6–8 years depending on swallowing ability. Cannot be opened and sprinkled — not designed for this.
CD/SR Tablets (375 mg, 500 mg)	⛔ Not suitable for children <12 years	Must be swallowed whole; cannot be crushed, split, or chewed. Use only in adolescents ≥12 years who can swallow tablets.

Palatability

Cefaclor oral suspension has a fruity/strawberry flavour (varies by manufacturer) and is generally well-accepted by children.
If the child refuses the suspension, it may be mixed with a small amount of cold milk, formula, fruit juice, or soft food immediately before administration — administer within 5 minutes of mixing; do not store the mixture.
⚠️ Do not mix with hot liquids (may degrade the drug).
Bitter aftertaste may occur with some generic brands — switching brands may improve acceptance if the child consistently refuses.

Age-Specific Pharmacokinetic Differences

Age Group	PK Notes
Neonates (<28 days)	Prolonged half-life (2–3 hours) due to immature renal function; lower clearance per kg. Dosing interval should be extended. See Neonatal Dosing below.
Infants (1–12 months)	Renal maturation occurs rapidly; by 6–12 months, clearance approaches older paediatric values. Half-life ~1.0–1.5 hours. Standard paediatric mg/kg dosing applies from ~1 month.
Children (1–12 years)	Higher weight-normalised clearance compared to adults — may require dosing at the upper end of the mg/kg range for optimal T > MIC. Half-life ~0.5–0.8 hours.
Adolescents (≥12 years or ≥40 kg)	Use adult dosing — see Part 2.

ℹ️ Absorption via the PEPT1 intestinal peptide transporter is functional from early infancy, ensuring good oral bioavailability across all paediatric age groups.

Adolescent Transition

≥12 years AND ≥40 kg: Use adult dosing schedules (IR capsules 250–500 mg TDS, or CD/SR tablets at adult doses if able to swallow tablets whole with food) — see Part 2.
12–15 years but <40 kg: Continue weight-based paediatric dosing up to the adult maximum per dose.
CD/SR formulation: May be used in adolescents ≥12 years who can swallow tablets whole with food.

Neonatal Dosing

⚠️ Neonatal use — NICU supervision only

Parameter	Details
Age group	<28 days of life (both preterm and term)
Status	Limited data. Cefaclor is rarely the antibiotic of choice in neonatal infections. Neonatal sepsis protocols in India (NNF/IAP) recommend ampicillin + gentamicin (first-line) or cefotaxime-based regimens (Gram-negative/late-onset). Oral cefaclor has no established role in neonatal sepsis, meningitis, or serious infections.
Potential neonatal use	Very limited — may be considered only as step-down oral therapy for a confirmed cefaclor-susceptible mild UTI or superficial skin infection in a clinically stable, feeding neonate approaching 28 days of age, under neonatologist guidance. Amoxicillin or amoxicillin-clavulanate oral suspension is generally preferred for oral step-down.
Dose (if used — exceptional circumstances only)	10 mg/kg/dose every 12 hours (BD) — extended interval due to immature renal clearance. Based on extrapolation from limited pharmacokinetic data; no validated neonatal dosing regimen exists.
Maximum absolute dose	Dosing in neonates is weight-based and will inherently remain well below adult doses.
Gestational age considerations	Preterm neonates (<37 weeks gestational age) have further reduced renal function — avoid cefaclor unless no other option exists and susceptibility is confirmed. Prefer parenteral agents. Term neonates (≥37 weeks) have slightly better renal function but still significantly immature.
Recommendation	⛔ No established neonatal dosing for routine use. Use only under NICU/neonatologist supervision in exceptional circumstances. Prefer ampicillin, gentamicin, or cefotaxime per NNF/IAP neonatal guidelines.

Primary Indications — Paediatric (Approved / Standard in India)

1. Upper Respiratory Tract Infections (URTI) — Acute Otitis Media (AOM), Acute Bacterial Pharyngitis / Tonsillitis (GAS), Acute Bacterial Sinusitis

ℹ️ These three conditions are combined because cefaclor dosing is identical across them (20–40 mg/kg/day TDS — only duration differs). Condition-specific notes are provided separately below the dosing table.

Weight-Based Dosing Table (IR Oral Suspension / Capsules)

Severity	Dose (mg/kg/day)	Divided into	Frequency	Maximum Absolute Dose	Duration
Standard (mild–moderate)	20 mg/kg/day	3 equal doses	Every 8 hours (TDS)	Max 250 mg per dose; Max 750 mg per day	See condition-specific notes
Higher dose (moderate–severe / treatment failure)	40 mg/kg/day	3 equal doses	Every 8 hours (TDS)	Max 500 mg per dose; Max 1500 mg per day	See condition-specific notes
≥40 kg or ≥12 years	Adult dosing: 250–500 mg TDS (capsules)	—	Every 8 hours (TDS)	Max 500 mg per dose; Max 1500 mg per day	See condition-specific notes

Practical Volume Dosing Guide — 125 mg/5 mL Suspension

Body Weight	Standard (20 mg/kg/day) — Per Dose TDS	Volume per Dose	Higher (40 mg/kg/day) — Per Dose TDS	Volume per Dose
5 kg	~33 mg	1.3 mL	~67 mg	2.7 mL
7 kg	~47 mg	1.9 mL	~93 mg	3.7 mL
10 kg	~67 mg	2.7 mL	~133 mg	5.3 mL
12 kg	~80 mg	3.2 mL	~160 mg	6.4 mL
15 kg	100 mg	4 mL	200 mg	8 mL
20 kg	~133 mg	5.3 mL	~267 mg	10.7 mL(switch to 250 mg/5 mL)

Practical Volume Dosing Guide — 250 mg/5 mL Suspension (for heavier children)

Body Weight	Standard (20 mg/kg/day) — Per Dose TDS	Volume per Dose	Higher (40 mg/kg/day) — Per Dose TDS	Volume per Dose
20 kg	~133 mg	2.7 mL	~267 mg	5.3 mL
25 kg	~167 mg	3.3 mL	~333 mg	6.7 mL
30 kg	200 mg	4 mL	~400 mg	8 mL
35 kg	~233 mg	4.7 mL	~467 mg	9.3 mL
≥40 kg	Use adult dosing (capsules)	—	Use adult dosing (capsules)	—

ℹ️ Use an oral syringe for accurate dosing, especially for volumes <5 mL. Household teaspoons are inaccurate and should not be used.

Condition-Specific Notes — A. Acute Otitis Media (AOM)

Duration:10 days for children <2 years or with severe symptoms. 7 days may be adequate for children ≥2 years with mild–moderate, unilateral AOM and reliable follow-up.
When to prefer cefaclor: Second-line oral cephalosporin option when amoxicillin (first-line per IAP guidelines: 80–90 mg/kg/day divided BD or TDS × 10 days) has failed after 48–72 hours, or in children with non-anaphylactic penicillin allergy. Cefaclor provides better beta-lactamase stability against H. influenzae and M. catarrhalis than amoxicillin alone.
When NOT to use:
- ⛔ Children with history of immediate/anaphylactic reaction to any penicillin or cephalosporin (urticaria, angioedema, bronchospasm, anaphylaxis)
- ⛔ Complicated AOM (mastoiditis, facial nerve palsy, intracranial complications) — requires hospitalisation and parenteral antibiotics
- ⛔ AOM with tympanic membrane perforation and active discharge persisting >6 weeks (chronic suppurative otitis media / CSOM — different management; requires topical + systemic approach, often with anti-pseudomonal/anaerobic coverage)
- ⛔ Otitis media with effusion (OME) — this is NOT a bacterial infection and does not warrant antibiotics
Watchful waiting option: IAP guidelines (aligned with AAP 2013/updated) support 48–72 hours of observation (analgesics only, no antibiotics) in children ≥6 months with unilateral, non-severe AOM — with a safety-net antibiotic prescription (caregiver is given a prescription to fill only if symptoms worsen or do not improve). This reduces unnecessary antibiotic use and is underutilised in Indian practice.
Preferred alternatives in India:
- First-line: High-dose amoxicillin 80–90 mg/kg/day divided BD or TDS × 10 days (IAP, ICMR)
- Second-line (amoxicillin failure): Amoxicillin-clavulanate 80–90 mg/kg/day (amoxicillin component) divided BD × 10 days
- Penicillin-allergic (non-anaphylactic): Cefaclor 40 mg/kg/day TDS, OR cefuroxime axetil 30 mg/kg/day BD
- Penicillin-allergic (anaphylactic type): Azithromycin 10 mg/kg Day 1, then 5 mg/kg Days 2–5
NLEM status for this indication: Cefaclor is not in NLEM. Amoxicillin is the NLEM-listed antibiotic for paediatric AOM.
Time to expected clinical response: Ear pain and fever should improve within 48–72 hours.
Treatment failure criteria: Persistent fever, worsening ear pain, or new symptoms at 48–72 hours:
1. If initially on standard dose (20 mg/kg/day) → escalate to higher dose (40 mg/kg/day)
2. If already on higher dose or initially on cefaclor as second-line → switch to amoxicillin-clavulanate
3. For severe/refractory cases → consider tympanocentesis for culture or ceftriaxone IM (single dose 50 mg/kg, max 1 g)
4. New post-auricular swelling suggesting mastoiditis → urgent ENT referral + hospitalisation + parenteral antibiotics
Mandatory baseline investigations: Otoscopic examination (mandatory). Tympanometry (recommended if available). No blood tests required for uncomplicated AOM.
Specialist initiation: Not required — appropriate for primary care / paediatrician prescribing. ENT referral for: recurrent AOM (≥3 episodes in 6 months or ≥4 in 12 months), complications, hearing concerns, consideration for tympanostomy tubes.
Indian guideline source: IAP Guidelines for Management of AOM; ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes (2019); API Textbook of Medicine.
Key safety warning: ⚠️ SSLR risk — higher with cefaclor than other cephalosporins, especially during second or subsequent courses. Counsel caregivers (see SSLR box above).

Condition-Specific Notes — B. Acute Bacterial Pharyngitis / Tonsillitis (GAS)

Duration: ⚠️ 10 days — non-negotiable. Shorter courses are inadequate for GAS eradication and fail to prevent rheumatic fever. This is critically important in the Indian context where rheumatic heart disease remains a major cause of cardiovascular morbidity in children and young adults. India has the world’s highest burden of rheumatic heart disease.
When to prefer cefaclor: Non-anaphylactic penicillin allergy; amoxicillin intolerance (GI); recurrent GAS pharyngitis where carrier state with co-pathogen (beta-lactamase-producing H. influenzae) may be contributing to amoxicillin failure. Some meta-analyses suggest second-generation cephalosporins achieve marginally higher bacteriological cure rates than penicillin V for GAS pharyngitis, but this does not change first-line recommendations.
When NOT to use:
- ⛔ Anaphylactic penicillin or cephalosporin allergy — use azithromycin or clindamycin
- ⛔ Viral pharyngitis — the most common cause of sore throat in children. Confirm bacterial aetiology before prescribing (modified McIsaac score ≥3, RADT, or throat culture). Do not prescribe antibiotics for clinical score <3 without microbiological confirmation.
- ⛔ Peritonsillar abscess — requires drainage + parenteral antibiotics
Compliance strategy for India: ⚠️ If compliance with a 10-day oral course is doubtful (very common in Indian primary care/PHC settings — symptom resolution at day 3–4 leads to premature discontinuation), single-dose IM benzathine penicillin G is the preferred strategy:
- <27 kg: 6 lakh (600,000) units IM × 1 dose
- ≥27 kg: 12 lakh (1,200,000) units IM × 1 dose
- This provides reliable GAS eradication with a single visit and is the most effective strategy for rheumatic fever prevention in resource-limited settings (IAP/ICMR recommendation).
Preferred alternatives in India:
- First-line: Amoxicillin 50 mg/kg/day (max 1 g/day) divided BD or TDS × 10 days (IAP first-line oral)
- Alternative first-line: Penicillin V 250 mg BD–TDS × 10 days (limited availability in India)
- Compliance concerns: IM benzathine penicillin G single dose (see above)
- Penicillin-allergic (non-anaphylactic): Cephalexin 25–50 mg/kg/day divided BD × 10 days OR cefaclor 20 mg/kg/day TDS × 10 days
- Penicillin-allergic (anaphylactic type): Azithromycin 12 mg/kg/day × 5 days (max 500 mg/day) OR clindamycin 20 mg/kg/day divided TDS × 10 days (max 1.8 g/day)
NLEM status: Amoxicillin and benzathine penicillin G are NLEM-listed. Cefaclor is not.
Time to expected clinical response: Fever and severe throat pain improve within 24–48 hours. Child is considered non-infectious after 24 hours of effective therapy → can return to school.
Treatment failure criteria: Persistent fever and symptoms at 72 hours, or clinical relapse within 2 weeks → obtain throat culture, assess compliance, consider amoxicillin-clavulanate or clindamycin; exclude peritonsillar abscess.
Mandatory baseline investigations: Throat examination (mandatory). RADT or throat culture (recommended — particularly important in children aged 3–15 years who are at highest risk for rheumatic fever). ℹ️ ASO titre is NOT useful for acute diagnosis — it reflects past streptococcal infection, not current pharyngitis. Do not order ASO to diagnose acute GAS pharyngitis.
Specialist initiation: Not required. Appropriate for primary care / paediatrician prescribing.
Indian guideline source: IAP Guidelines; ICMR Treatment Guidelines for Antimicrobial Use (2019); Indian Academy of Pediatrics Revised Guidelines for Rheumatic Fever (2008, updated practice).

Condition-Specific Notes — C. Acute Bacterial Sinusitis

Duration:10–14 days (standard). Some guidelines suggest treating for 7 days beyond symptom resolution.
Diagnosis in children — when to prescribe antibiotics: Bacterial sinusitis should be diagnosed when upper respiratory symptoms (nasal discharge, cough) persist for ≥10 days without improvement, or when there is severe onset (high fever ≥39°C with purulent nasal discharge for ≥3 consecutive days), or worsening after initial improvement (“double worsening”). ⚠️ Do NOT prescribe antibiotics for simple viral URI — the vast majority of “sinusitis” in children is viral and self-limiting.
When to prefer cefaclor: Second-line when amoxicillin or amoxicillin-clavulanate is not tolerated. Covers beta-lactamase-producing H. influenzae and M. catarrhalis — key sinusitis pathogens.
When NOT to use:
- ⛔ Chronic sinusitis (>12 weeks) — often polymicrobial including anaerobes; requires broader-spectrum and longer-duration therapy, often ENT involvement
- ⛔ Complicated sinusitis (orbital cellulitis, subperiosteal/orbital abscess, intracranial extension) — urgent hospitalisation + parenteral antibiotics + imaging + ENT/ophthalmology
- ⛔ Suspected fungal sinusitis (immunocompromised children)
Preferred alternatives in India: Amoxicillin-clavulanate (first-line — IAP, API); amoxicillin alone (for mild cases in low-resistance settings).
Time to expected clinical response: 48–72 hours. If no improvement by day 3, reassess diagnosis, consider imaging (CT sinuses), and switch to amoxicillin-clavulanate or refer to ENT.
Specialist initiation: Not required for uncomplicated ABRS. ENT referral for chronic, recurrent, or complicated sinusitis; nasal polyposis; suspected fungal sinusitis.
Indian guideline source: IAP Guidelines; API Textbook of Medicine; ENT specialist consensus in India.

2. Lower Respiratory Tract Infections — Paediatric (Mild CAP, Acute Bronchitis with Bacterial Superinfection)

Weight-Based Dosing Table

Severity	Dose (mg/kg/day)	Divided into	Frequency	Maximum Absolute Dose	Duration
Standard	20 mg/kg/day	3 equal doses	Every 8 hours (TDS)	Max 500 mg per dose; Max 1500 mg per day	5–7 days
Higher dose (moderate infection)	40 mg/kg/day	3 equal doses	Every 8 hours (TDS)	Max 500 mg per dose; Max 1500 mg per day	7–10 days
≥40 kg or ≥12 years	Adult dosing	—	TDS	As adult	As per indication

Condition-Specific Notes — A. Acute Bronchitis with Suspected Bacterial Superinfection

⚠️ Most cases of acute bronchitis in children are viral and DO NOT require antibiotics. Antibiotics are recommended ONLY when bacterial superinfection is suspected (purulent sputum >7–10 days, high-grade fever, worsening trajectory, child with underlying chronic lung disease or immunosuppression).
Duration: 5–7 days (if antibiotics indicated).
Preferred alternatives in India: Amoxicillin or amoxicillin-clavulanate (first-line). Cefaclor is second-line.
Time to expected clinical response: 48–72 hours for fever. Cough may persist for 2–3 weeks even after successful bacterial clearance — counsel caregivers that persistent cough does not necessarily mean treatment failure.

Condition-Specific Notes — B. Mild Community-Acquired Pneumonia (CAP) — Outpatient

When to prefer cefaclor: Very limited first-line role. May be considered only when culture/sensitivity confirms a cefaclor-susceptible typical pathogen (S. pneumoniae, H. influenzae) and atypical coverage is not needed.
When NOT to use:
- ⛔ Severe pneumonia (WHO classification: chest indrawing, danger signs — inability to drink, lethargy, convulsions, stridor) — requires hospitalisation and parenteral antibiotics
- ⛔ Suspected atypical pneumonia — Mycoplasma pneumoniae is the most common CAP pathogen in school-age children (5–15 years) in India. Cefaclor has zero activity against Mycoplasma, Chlamydophila, or Legionella. If atypical pneumonia is suspected (school-age child, subacute onset, non-productive cough, wheeze, extrapulmonary features), a macrolide (azithromycin 10 mg/kg day 1, then 5 mg/kg days 2–5) is required.
- ⛔ Neonatal pneumonia (<2 months — always requires hospitalisation and parenteral antibiotics)
- ⛔ Suspected Staphylococcal pneumonia (e.g., post-measles, post-influenza pneumonia with pneumatocoeles) — cefaclor’s anti-staphylococcal activity is inferior to first-generation cephalosporins and anti-staphylococcal penicillins
- ⛔ Aspiration pneumonia (anaerobic coverage needed — amoxicillin-clavulanate or clindamycin)
- ⛔ Complicated pneumonia (empyema, necrotising pneumonia, lung abscess)
Preferred alternatives in India (IAP/ICMR guidelines):
- <5 years (typical pathogen focus): Amoxicillin 80–90 mg/kg/day divided BD × 5 days (IAP/WHO first-line for non-severe CAP). Amoxicillin-clavulanate if beta-lactamase concern.
- ≥5 years (atypical pathogen likelihood increases): Amoxicillin + azithromycin combination, or azithromycin alone if atypical presentation dominant.
- Penicillin allergy (non-anaphylactic): Cefaclor or cefuroxime axetil.
- Cefaclor monotherapy is not recommended as empirical first-line for paediatric CAP.
NLEM status: Amoxicillin is the NLEM-listed first-line oral antibiotic for paediatric CAP.
Duration: Minimum 5 days; patient should be afebrile ≥48 hours before stopping. 7–10 days for moderate infection.
Mandatory baseline investigations: Respiratory rate count (mandatory — WHO/IMNCI criteria for pneumonia diagnosis in children). SpO₂ by pulse oximetry (recommended — if <92% at sea level, hospitalise). Chest X-ray (recommended for suspected pneumonia but not mandatory for outpatient non-severe CAP per WHO/IAP).
Time to expected clinical response: Fever should improve within 48–72 hours. Cough may persist for 1–2 weeks.
Treatment failure criteria: Persistent high fever at 48–72 hours, worsening tachypnoea, new danger signs → hospitalise, obtain blood culture, chest X-ray, switch to parenteral antibiotics.
Specialist initiation: Not required for non-severe outpatient CAP. Paediatric/Pulmonology referral for severe, complicated, or recurrent pneumonia.
Indian guideline source: IAP Guidelines for Management of CAP in Children; ICMR Treatment Guidelines (2019); WHO Pocket Book of Hospital Care for Children (supportive reference).
Key safety warning: ⚠️ Cefaclor monotherapy for paediatric CAP risks treatment failure when atypical organisms are the cause. In school-age children (5–15 years), always consider adding or substituting a macrolide.

3. Urinary Tract Infections — Paediatric (Uncomplicated Lower UTI / Acute Cystitis)

Weight-Based Dosing Table

Severity	Dose (mg/kg/day)	Divided into	Frequency	Maximum Absolute Dose	Duration
Standard	20 mg/kg/day	3 equal doses	Every 8 hours (TDS)	Max 500 mg per dose; Max 1500 mg per day	7–10 days
Higher dose	40 mg/kg/day	3 equal doses	Every 8 hours (TDS)	Max 500 mg per dose; Max 1500 mg per day	7–10 days

Mandatory Clinical Notes — UTI (Paediatric)

⚠️ All paediatric UTIs (especially first episode) must have urine culture and sensitivity — empirical therapy should be guided by local antibiogram and modified once culture results are available (IAP guideline). This is mandatory, not optional.
When to prefer cefaclor: ONLY when culture confirms susceptibility and first-line agents (amoxicillin-clavulanate, cephalexin, nitrofurantoin) are not tolerated or available.
When NOT to use:
- ⛔ Febrile UTI / suspected pyelonephritis in children (especially <2 years): Any child with UTI + fever is presumed to have upper tract involvement → requires parenteral antibiotics initially (ceftriaxone IM/IV or aminoglycoside per IAP), with oral step-down guided by culture. Cefaclor is not adequate for pyelonephritis.
- ⛔ Complicated UTI (structural abnormality, obstruction, renal abscess)
- ⛔ ESBL-producing organism — cefaclor will be ineffective
- ⛔ Empirical UTI treatment without culture — ⚠️ In India, ESBL-producing E. coli prevalence in paediatric urine isolates is high (40–70% in many centres — ICMR AMR data). Empirical cephalosporin use for paediatric UTI without culture is strongly discouraged.
Preferred alternatives in India:
- Uncomplicated cystitis (afebrile, >2 years): Nitrofurantoin (if ≥1 month age, afebrile, lower UTI only), cotrimoxazole, or amoxicillin-clavulanate — culture-directed
- Febrile UTI / suspected pyelonephritis: Ceftriaxone IM/IV, amikacin/gentamicin IV (IAP/MoHFW) initially, then oral step-down
Mandatory baseline investigations: Urine culture — clean-catch midstream (toilet-trained), catheter specimen or suprapubic aspirate (infants/non-toilet-trained) — MANDATORY before starting antibiotics. Renal ultrasound (recommended). Serum creatinine (recommended if systemic illness).
Post-treatment work-up: Repeat urine culture to confirm eradication (especially <5 years). Renal ultrasound for all first febrile UTIs in children <2 years and in older children with recurrent UTI or atypical features. MCUG/VCUG (recommended in children <2 years after first febrile UTI to rule out vesicoureteral reflux — per IAP protocol).
Duration: 7–10 days for lower UTI; 10–14 days for pyelonephritis (but cefaclor is rarely appropriate for pyelonephritis).
Time to expected clinical response: Dysuria/frequency improve within 24–48 hours. Fever (if present) resolves within 48–72 hours.
Treatment failure criteria: Persistent symptoms at 48–72 hours → obtain/review urine culture, reassess. May need switch to parenteral therapy or broader-spectrum agent.
Specialist initiation: Paediatric Nephrology/Urology referral for: first febrile UTI in child <2 years, recurrent UTI, abnormal renal ultrasound, suspected VUR, structural abnormalities.
Indian guideline source: IAP Consensus Guidelines on UTI in Children (2011, updated practice); ICMR AMR surveillance; MoHFW operational guidelines.
Key safety warning: ⚠️ Never treat paediatric UTI empirically with cephalosporins in India without sending a urine culture. High ESBL prevalence makes empirical cephalosporin therapy unreliable.

4. Skin and Soft Tissue Infections — Paediatric (Uncomplicated)

Weight-Based Dosing Table

Severity	Dose (mg/kg/day)	Divided into	Frequency	Maximum Absolute Dose	Duration
Mild (localised impetigo, minor wound infection)	20 mg/kg/day	3 equal doses	TDS	Max 250 mg per dose; Max 750 mg per day	7 days
Moderate (cellulitis, extensive impetigo, larger wound infection)	40 mg/kg/day	3 equal doses	TDS	Max 500 mg per dose; Max 1500 mg per day	7–10 days

Mandatory Clinical Notes — SSTI (Paediatric)

When to prefer cefaclor: Alternative when cephalexin (preferred first-generation for Gram-positive skin infections) or amoxicillin-clavulanate is not available or tolerated. Reasonable for non-purulent cellulitis and streptococcal skin infections.
When NOT to use:
- ⛔ Purulent skin infections (abscess, furuncle, carbuncle): Frequently MRSA in Indian practice. Cefaclor has NO MRSA activity. Incision and drainage is the primary intervention; if systemic antibiotics needed, use cotrimoxazole, clindamycin, or doxycycline (≥8 years only for doxycycline).
- ⛔ Animal or human bite wounds: Require anaerobic + Pasteurella/Eikenella coverage → amoxicillin-clavulanate is the drug of choice. Cefaclor is inadequate.
- ⛔ Deep-seated or necrotising infections (necrotising fasciitis, osteomyelitis, septic arthritis) — require parenteral antibiotics and surgical consultation.
For impetigo specifically: Localised impetigo (<5 lesions, small area) → topical mupirocin 2% or fusidic acid 2% is first-line (IAP/IADVL). Systemic antibiotics (including cefaclor) only for extensive, spreading, or bullous impetigo, or when topical therapy has failed. This follows antimicrobial stewardship principles.
Preferred alternatives in India: Cephalexin (first-generation — narrower spectrum, preferred per stewardship); amoxicillin-clavulanate; cloxacillin/flucloxacillin (if MSSA confirmed).
Time to expected clinical response: 48–72 hours. Mark borders of cellulitis with a skin marker for objective tracking.
Key safety warning: ⚠️ Community-acquired MRSA (CA-MRSA) prevalence in Indian paediatric SSTI is increasing. Do not assume staphylococcal infection is MSSA without culture support in areas of high MRSA prevalence.
Specialist initiation: Not required for uncomplicated SSTI. Surgical referral for abscess drainage. Infectious Disease referral for deep-seated or non-resolving infections.
Indian guideline source: IAP Infectious Disease Chapter guidelines; IADVL guidelines for paediatric skin infections.

Secondary Indications — Paediatric (Off-Label)

1. Low-Dose Prophylaxis for Recurrent UTI in Children with Vesicoureteral Reflux (VUR)

Status: OFF-LABEL but accepted standard practice in India (IAP Paediatric Nephrology guidelines support antibiotic prophylaxis in VUR grades III–V with recurrent febrile UTI or renal scarring)
Dose: 10 mg/kg/dose once daily at bedtime (approximately one-third to one-half of the therapeutic daily dose)
Maximum dose: Max 250 mg per dose; Max 250 mg per day (prophylactic dosing)
Duration: 6–12 months minimum; may continue until VUR resolves spontaneously or is surgically corrected — duration guided by Paediatric Nephrologist/Urologist
Specialist only: ⚠️ Yes — Paediatric Nephrology or Urology supervision mandatory. Decision to start and continue prophylaxis must be based on VUR grade, breakthrough UTI frequency, renal scarring status, and ongoing imaging follow-up.
Clearly marked: OFF-LABEL but accepted standard practice in India
Evidence basis: Prophylactic antibiotics for VUR evaluated in several paediatric RCTs (RIVUR trial — used cotrimoxazole; Swedish Reflux Trial). Overall evidence supports modest benefit in reducing febrile UTI recurrence, particularly in high-grade VUR. Cefaclor is one of several agents used; nitrofurantoin and cotrimoxazole are more commonly recommended and have stronger direct evidence.
Level of evidence quality:Moderate — Paediatric RCTs exist for the principle of antibiotic prophylaxis in VUR. Data specific to cefaclor (vs nitrofurantoin or cotrimoxazole) is limited — evidence is extrapolated from the class and from clinical practice.
Preferred alternatives for UTI prophylaxis in children:
- Nitrofurantoin 1–2 mg/kg at bedtime (most commonly recommended in India and internationally)
- Cotrimoxazole 1–2 mg/kg (TMP component) at bedtime (widely used in Indian paediatric practice)
- Cephalexin 10 mg/kg at bedtime (preferred cephalosporin for this purpose — first-generation, narrower spectrum)
Clinical note: ⚠️ Long-term cephalosporin use for UTI prophylaxis may promote ESBL-producing organism selection. Prefer nitrofurantoin or cotrimoxazole when possible. Current paediatric nephrology trend (including in Indian practice) is toward more selective use of antibiotic prophylaxis — not all children with VUR require prophylaxis. IAP and Indian paediatric nephrology consensus increasingly recommend prophylaxis mainly for high-grade VUR (Grade III–V) with recurrent febrile UTI or renal scarring. Periodic urine cultures (every 3–6 months) and annual renal ultrasound recommended during prophylaxis.
Age restriction: May be used from 1 month of age under specialist guidance.
Indian guideline source: IAP Standard Treatment Guidelines — Paediatric Nephrology; IAP Consensus Statement on UTI Prophylaxis.

ℹ️ AOM prophylaxis — explicitly NOT recommended: Some older literature examined antibiotic prophylaxis for recurrent AOM. Current IAP and international guidelines do not recommend routine antibiotic prophylaxis for recurrent AOM due to minimal benefit and significant antimicrobial resistance concerns. This is not listed as an off-label indication.

ℹ️ No other well-documented secondary (off-label) paediatric indications for cefaclor were identified with sufficient evidence to include in this formulary.

RENAL ADJUSTMENT

ℹ️ eGFR Formula Specification: The dosing adjustments below are primarily based on creatinine clearance (CrCl) estimated by the Cockcroft-Gault equation, consistent with the original pharmacokinetic studies for cefaclor. CKD-EPI eGFR values may differ, especially in elderly patients, extreme body weights, and advanced CKD. In elderly patients (≥60 years), Cockcroft-Gault CrCl may yield lower values than CKD-EPI eGFR due to the effect of body weight and age — this could lead to more conservative (lower) dosing if Cockcroft-Gault is used. Either estimate is acceptable; the key is to assess renal function before prescribing in at-risk patients.

ℹ️ For paediatric patients: Use the Schwartz formula (bedside Schwartz equation using serum creatinine) for estimating GFR.

ℹ️ Key Pharmacokinetic Rationale: Cefaclor is primarily excreted by the kidneys (60–85% unchanged). Half-life is prolonged from ~0.6–0.9 hours (normal renal function) to ~2.3–2.8 hours (CrCl <10 mL/min). However, due to the relatively wide therapeutic index of cefaclor, dose adjustments are generally required only in moderate-to-severe renal impairment.

Adult Renal Dosing Adjustment Table

eGFR / CrCl (mL/min)	IR Capsule / Suspension Dose	CD/SR Tablet Dose	Notes
>60	No adjustment. Standard dosing: 250–500 mg TDS	No adjustment. Standard dosing: 375–500 mg BD	Normal renal function
30–60	No adjustment required. Standard dosing with monitoring.	No adjustment required. Standard dosing.	Monitor for GI adverse effects. Half-life only modestly prolonged. Standard doses maintain adequate serum levels.
15–30	Reduce dose by 50% or extend interval: 250 mg BD (for standard infections) to 500 mg BD (for severe infections)	Consider dose reduction to 375 mg BD or switch to IR formulation for better dose titration	⚠️ Monitor for drug accumulation. Watch for GI and CNS adverse effects (headache, dizziness). Assess clinical response.
<15 (non-dialysis)	250 mg BD (for standard infections); 250 mg TDS (for severe infections — do not exceed this). Some authorities recommend no more than 1 g/day regardless of indication severity.	Not recommended — switch to IR formulation for better dose control	⚠️ Half-life prolonged to ~2.3–2.8 hours. Drug accumulation likely. Use with caution and only if no better alternative exists. Consider alternative agents.
Haemodialysis	250 mg supplemental dose after each dialysis session (in addition to reduced maintenance dosing as for CrCl <15). Cefaclor is moderately dialysable (~55% removed per 4-hour session).	Not recommended — use IR formulation	💡 Time the maintenance dose so it is taken AFTER the dialysis session to avoid immediate removal. On non-dialysis days, use the CrCl <15 dosing schedule.
Peritoneal dialysis	Use CrCl <15 dosing: 250 mg BD. Cefaclor is poorly removed by peritoneal dialysis — no supplemental dose required.	Not recommended — use IR formulation	Monitor for accumulation
CRRT	Data limited. Use CrCl 15–30 dosing as starting point: 250–500 mg BD. Adjust based on clinical response.	Not recommended — use IR formulation	⚠️ CRRT clearance varies significantly depending on filter type, flow rate, and modality (CVVH vs CVVHDF). Consult clinical pharmacologist or ICU pharmacist if available. Cefaclor is rarely the antibiotic of choice in CRRT patients — consider parenteral alternatives.

Paediatric Renal Dosing Adjustment

Use the Schwartz formula for estimating GFR in paediatric patients.

GFR (mL/min/1.73m²)	Dose Adjustment	Notes
>60	No adjustment. Use standard mg/kg dosing.	—
30–60	No adjustment generally required for short courses. Monitor for adverse effects.	—
10–30	Reduce dose by 50% — give half the standard mg/kg/dose at the same frequency (TDS), OR extend interval to BD dosing at standard mg/kg/dose.	Paediatric Nephrology oversight recommended.
<10	Reduce dose by 50% AND extend interval — give half the standard mg/kg/dose BD. Use only if no better alternative exists.	⚠️ Paediatric Nephrology oversight mandatory.
Haemodialysis	Supplemental dose after dialysis: 50–100% of a single standard weight-based dose.	Paediatric Nephrologist guidance required.
Peritoneal dialysis	Use GFR <10 dosing. No supplemental dose required (poorly removed by PD).	Monitor for accumulation.

CD/SR Tablets in Renal Impairment — Special Note

⚠️ CD/SR (modified-release) tablets have not been specifically studied in renal impairment. The sustained-release mechanism depends on normal GI transit and is independent of renal function, but the prolonged elimination half-life in renal impairment means that drug accumulation may be more significant with CD/SR formulations (which already produce sustained plasma levels). For all patients with CrCl <30 mL/min, use the IR formulation (capsule or suspension) rather than CD/SR tablets to allow more precise dose adjustment and avoid unpredictable accumulation.

Augmented Renal Clearance (ARC)

ℹ️ ARC (CrCl >130 mL/min) in young, non-elderly ICU patients (sepsis, trauma, burns) could theoretically lead to enhanced cefaclor elimination and subtherapeutic levels. However, for cefaclor specifically, ARC is unlikely to be clinically significant because:

1. Cefaclor is rarely the antibiotic of choice in ICU settings where ARC occurs
2. The clinical scenario of a patient sick enough to have ARC would typically prompt use of a parenteral antibiotic rather than dose-escalation of oral cefaclor

No specific ARC dose increase recommendation for cefaclor. If cefaclor is used in an exceptional circumstance in a patient with suspected ARC, use the maximum recommended dose (500 mg TDS for IR) and reassess whether a parenteral antibiotic would be more appropriate.

Source of Recommendations

Renal dosing recommendations derived from CDSCO product insert data, Goodman & Gilman’s The Pharmacological Basis of Therapeutics (pharmacokinetic principles for cephalosporins), and standard clinical pharmacology references. No specific Indian guideline provides cefaclor-specific renal dosing beyond the product insert.

HEPATIC ADJUSTMENT

Formal Child-Pugh-Based Data

ℹ️ No formal Child-Pugh-based dosing studies exist for cefaclor. The clinical guidance below is based on pharmacokinetic principles.

Pharmacokinetic Rationale

Factor	Assessment
Hepatic metabolism fraction	Low — cefaclor is primarily excreted renally (60–85% unchanged). Hepatic metabolism is a minor elimination pathway. It does not undergo significant CYP450 metabolism.
Hepatic extraction ratio	Low — consistent with minimal first-pass hepatic effect
Active metabolite accumulation	No clinically relevant active metabolites. No accumulation concern in liver disease.
Protein binding	~22–25% — low protein binding. Even in severe hypoalbuminaemia (as seen in decompensated cirrhosis), the free fraction increase is clinically insignificant.
Biliary excretion	Minor route — small fraction excreted via bile. Not expected to be significantly altered in cholestatic liver disease.

Clinical Guidance by Severity

Hepatic Impairment	Recommendation	Notes
Mild (Child-Pugh A)	No dose adjustment required. Use standard dosing.	No clinically significant PK changes expected.
Moderate (Child-Pugh B)	No dose adjustment required. Use standard dosing.	Monitor for adverse effects, particularly GI tolerance — patients with portal hypertension/gastropathy may have increased GI sensitivity. Check LFTs at baseline if not already available.
Severe (Child-Pugh C)	No dose adjustment required based on hepatic metabolism alone.	⚠️ However: patients with severe hepatic impairment often have concurrent renal dysfunction (hepatorenal syndrome) → assess renal function and adjust dose for renal impairment if present (see Renal Adjustment section above). Patients with ascites may have altered Vd — clinical significance for cefaclor is limited due to its relatively low Vd (~0.24–0.35 L/kg).

Summary Statement

✅ Cefaclor does NOT require dose adjustment for hepatic impairment alone. Hepatic metabolism is a minor elimination pathway, protein binding is low, and no active metabolites accumulate. The main clinical concern in patients with liver disease is concurrent renal impairment — dose-adjust for renal function, not liver function.

💡 Clinical Pearl [Practice-based]: Cefaclor is one of the safest antibiotics with respect to the liver — there is essentially no hepatic dose adjustment concern. This makes it a reasonable choice (within its spectrum) for patients with liver disease who have concurrent infections, provided the infection is caused by a susceptible organism and the drug is not being used where a better alternative exists.

Concurrent Hepatotoxin Note

ℹ️ Cefaclor is not significantly hepatotoxic. Rare cases of transient transaminase elevation have been reported (<0.1%) but clinically significant hepatotoxicity is very uncommon.

No specific additional caution is required when co-prescribing with common hepatotoxic drugs used in Indian practice (rifampicin, isoniazid, pyrazinamide, methotrexate, valproate, antiretrovirals, chronic/high-dose paracetamol). Standard monitoring protocols for these hepatotoxic drugs apply irrespective of cefaclor co-prescription.

⚠️ Important caveat: If unexplained LFT elevation occurs during cefaclor therapy in a patient also receiving hepatotoxic drugs, consider all potential causes — do not assume cefaclor is the sole culprit without thorough assessment. Conversely, do not dismiss cefaclor as a possible contributor solely because it is “rarely hepatotoxic.”

CONTRAINDICATIONS

⛔ Absolute contraindications — the drug must NEVER be used in these situations.

1. Known Hypersensitivity to Cefaclor

⛔ History of any allergic reaction to cefaclor itself — including prior urticaria, angioedema, bronchospasm, anaphylaxis, or serum sickness-like reaction (SSLR) attributed to cefaclor.

Clinical rationale: Re-exposure to cefaclor after a previous allergic reaction carries a high risk of recurrence, potentially with greater severity. SSLR in particular has a documented increased incidence and severity with repeated cefaclor courses. Document all cefaclor reactions in the patient’s permanent medical records and allergy list.

2. Known Anaphylaxis to Any Cephalosporin

⛔ History of immediate/anaphylactic-type hypersensitivity (Type I: urticaria, angioedema, bronchospasm, hypotension, anaphylactic shock) to ANY cephalosporin — regardless of generation.

Clinical rationale: Structural similarity within the cephalosporin class (shared beta-lactam ring + dihydrothiazine ring) means IgE-mediated cross-reactivity between cephalosporins is significant. The risk is highest for cephalosporins sharing the same R1 side chain (see cross-reactivity section below).

3. Known Anaphylaxis to Any Penicillin (with Important Nuance)

⛔ History of immediate/anaphylactic-type hypersensitivity to ANY penicillin (amoxicillin, ampicillin, penicillin V, penicillin G, cloxacillin, piperacillin, etc.) — when the reaction was confirmed anaphylaxis (documented cardiovascular collapse, laryngeal oedema, severe bronchospasm, or generalised urticaria requiring adrenaline).

Clinical rationale: Cross-reactivity between penicillins and cephalosporins is estimated at ~1–2% overall for IgE-mediated reactions. However, the risk is higher for cephalosporins that share similar R1 side chains with the offending penicillin. Cefaclor’s R1 side chain (phenylglycyl group) is structurally similar to that of aminopenicillins (ampicillin, amoxicillin) — making cross-reactivity between cefaclor and aminopenicillins potentially higher than the general 1–2% class estimate.

ℹ️ Note: Non-anaphylactic penicillin reactions (delayed maculopapular rash, GI intolerance) are listed under Cautions, not Contraindications — cefaclor can generally be used cautiously in these patients.

Allergy Cross-Reactivity — Detailed Guidance

Related Drug/Class	Cross-Reactivity with Cefaclor	Nature	Clinical Action
Cephalexin, Cephradine	Highest — share identical R1 side chain (phenylglycyl group)	Structure-based (predictable)	⛔ If anaphylaxis to cephalexin or cephradine → do NOT use cefaclor
Ampicillin, Amoxicillin (aminopenicillins)	Moderate-High — similar (but not identical) R1 side chain	Structure-based (partially predictable)	⛔ If anaphylaxis to aminopenicillins → avoid cefaclor; choose a cephalosporin with a dissimilar R1 side chain (e.g., cefixime, ceftriaxone — different R1) if cephalosporin needed, or use a non-beta-lactam
Penicillin V, Penicillin G (natural penicillins)	Low (~1%) — different R1 side chain	Partially structure-based	⚠️ Caution. If anaphylaxis confirmed → avoid all beta-lactams or use under specialist supervision with graded challenge if needed
Other cephalosporins (cefuroxime, cefixime, ceftriaxone, cefpodoxime)	Low — different R1 side chains	Cross-reactivity rate ~1–2% between dissimilar cephalosporins	⚠️ Generally safe to use cephalosporins with different R1 side chains after cefaclor allergy (except SSLR — see below)
Carbapenems (meropenem, imipenem)	Very low (<0.5–1%)	Shared beta-lactam ring but different ring structure	Generally safe. Can use carbapenem in penicillin/cephalosporin-allergic patients.
Aztreonam (monobactam)	Negligible (except cross-reactivity with ceftazidime — not relevant for cefaclor)	No shared ring structure with cefaclor	✅ Safe to use in cefaclor-allergic patients

SSLR cross-reactivity note: SSLR to cefaclor is NOT IgE-mediated — it is related to reactive metabolites unique to cefaclor’s chemical structure (delta-3 isomer formation). Patients with SSLR to cefaclor can generally tolerate other cephalosporins (cephalexin, cefuroxime, cefixime) safely, though caution is advised. ⛔ However, cefaclor must never be re-used after SSLR.

4. Established Cephalosporin-Induced Immune Haemolytic Anaemia

⛔ History of cephalosporin-induced immune haemolytic anaemia — re-exposure can trigger severe, potentially fatal haemolysis.

Clinical rationale: Cephalosporins (including cefaclor) can rarely cause immune-mediated haemolytic anaemia via drug-dependent antibodies. Re-challenge is contraindicated.

CAUTIONS

⚠️ High-Priority Cautions

These are conditions where serious harm is possible without active monitoring or dose adjustment. For each, specific monitoring is noted.

1. Non-Anaphylactic Penicillin Allergy

⚠️ Patients with a history of delayed, non-severe penicillin reactions (maculopapular rash appearing >72 hours after starting therapy, GI intolerance labelled as “allergy,” isolated mild pruritus without urticaria) — these patients can generally receive cephalosporins including cefaclor, but with informed caution.

Monitoring required:

Observe for ≥30 minutes after the first dose in a healthcare setting if feasible
Counsel the patient/caregiver on signs of allergic reaction (rash, swelling, breathing difficulty)
Have emergency medications available (adrenaline, antihistamines, corticosteroids)
If doubt exists about the nature of the previous penicillin reaction, consider allergist referral for skin testing before prescribing any beta-lactam — though allergist access is limited in most Indian settings

💡 Clinical Pearl [Evidence-based]: The historically quoted penicillin–cephalosporin cross-reactivity rate of 10% is outdated and was based on contamination of early penicillin preparations with cephalosporin traces. The actual IgE-mediated cross-reactivity rate is ~1–2% overall, and is R1 side chain–dependent. Many patients labelled “penicillin-allergic” in Indian practice do not have true IgE-mediated allergy. Careful history-taking can often de-label penicillin allergy and expand antibiotic options.

2. Renal Impairment (eGFR <30 mL/min)

⚠️ Cefaclor is primarily renally excreted (60–85% unchanged). In moderate-to-severe renal impairment, drug accumulation occurs and half-life is prolonged significantly (up to 2.3–2.8 hours when CrCl <10 mL/min vs 0.6–0.9 hours normally).

Monitoring required:

Assess renal function (serum creatinine, eGFR) before prescribing in patients with known or suspected renal disease, elderly patients, and patients on concurrent nephrotoxic drugs
Dose adjustment required for eGFR <30 mL/min — see Renal Adjustment (Part 3)
Monitor for signs of drug accumulation: increased GI side effects, headache, dizziness
Use IR formulation (not CD/SR) for CrCl <30 mL/min to allow precise dose adjustment

3. History of Gastrointestinal Disease, Especially Colitis

⚠️ Patients with a history of antibiotic-associated colitis or Clostridioides difficile infection (CDI), or those with pre-existing inflammatory bowel disease (ulcerative colitis, Crohn’s disease), are at increased risk of CDI with any antibiotic, including cefaclor.

Monitoring required:

Counsel about signs of CDI: watery diarrhoea (≥3 loose stools/day), abdominal cramping, fever, blood/mucus in stool
If CDI suspected → discontinue cefaclor immediately, send stool for C. difficile toxin assay, and initiate specific CDI treatment (oral vancomycin or fidaxomicin per Indian guidelines)
Do not use antidiarrhoeal agents (loperamide) if CDI suspected — they can worsen toxin retention

4. Patients on Oral Anticoagulants (Warfarin)

⚠️ Although cefaclor does NOT possess the N-methylthiotetrazole (NMTT) side chain associated with direct hypoprothrombinemia (as seen with cefoperazone, cefamandole, cefotetan), any antibiotic — including cefaclor — can disrupt gut flora, reduce endogenous vitamin K synthesis, and potentiate warfarin effect.

Monitoring required:

Check INR at baseline and within 3–5 days of starting cefaclor in patients on stable warfarin therapy
Be alert for signs of over-anticoagulation (easy bruising, petechiae, gum bleeding, blood in urine/stool)
Adjust warfarin dose if INR rises above therapeutic range
The interaction is usually modest and self-limiting (resolves after the antibiotic course ends)

5. Seizure Disorders / Epilepsy

⚠️ Cephalosporins as a class have rare but documented pro-convulsant potential, particularly at high doses, in renal impairment (accumulation), or in patients with pre-existing seizure disorders. Cefaclor’s risk is lower than that of parenteral cephalosporins (cefepime, ceftazidime) due to limited CNS penetration at oral doses.

Monitoring required:

In patients with epilepsy: use standard doses, ensure renal function is adequate (dose-adjust in renal impairment to prevent accumulation)
If new-onset seizure occurs during cefaclor therapy in a renally impaired patient → consider drug accumulation as a contributing factor

Standard Cautions

These are conditions requiring awareness but carrying lower risk of serious harm.

6. Diabetes Mellitus — Urine Glucose Monitoring

ℹ️ Cefaclor can cause false-positive urine glucose results with copper reduction methods (Clinitest, Benedict’s reagent, Fehling’s solution). Glucose oxidase–based methods (Clinistix, Diastix, glucometer strips) are NOT affected.

This is clinically relevant in India where Benedict’s test is still used in some PHCs and smaller laboratories for urine glucose screening
Advise diabetic patients and laboratory staff that a positive urine glucose test during cefaclor therapy should be confirmed with a glucose oxidase method or blood glucose measurement
Blood glucose monitoring (glucometer) is not affected by cefaclor

7. Direct Coombs Test — Haematological Consideration

ℹ️ Cefaclor (like other cephalosporins) can cause a false-positive direct antiglobulin (Coombs) test without clinical haemolysis.

Clinically relevant if blood cross-matching is needed (e.g., pre-surgical, pre-transfusion) — inform the blood bank that the patient is on cefaclor
Also relevant if investigating for haemolytic anaemia — a positive Coombs test in a patient on cefaclor should not automatically be attributed to autoimmune haemolytic anaemia without further evaluation
True immune haemolytic anaemia from cefaclor is very rare (see Contraindications above and Serious Adverse Effects below)

8. Prolonged Antibiotic Courses (>14 Days)

ℹ️ Courses >14 days are uncommon for cefaclor but may occur in certain situations (e.g., chronic sinusitis management, although better alternatives exist).

Risk of superinfection (oral/vaginal candidiasis) increases with duration
Consider periodic CBC if course exceeds 14 days — rare cases of transient eosinophilia, neutropenia, or thrombocytopenia reported with prolonged cephalosporin use
Monitor LFTs if course is prolonged — rare transient transaminase elevation reported

9. Concomitant Nephrotoxic Drug Use

ℹ️ When cefaclor is co-prescribed with other nephrotoxic agents (aminoglycosides, NSAIDs, ACE inhibitors/ARBs, diuretics, amphotericin B, cisplatin, tenofovir), there is a theoretical additive risk of renal impairment — though this is primarily a concern with parenteral cephalosporins at high doses, not with oral cefaclor at standard doses.

Monitor renal function if cefaclor is combined with nephrotoxic drugs, especially in elderly patients or those with baseline renal impairment
In practice, this caution is rarely clinically significant for oral cefaclor

10. Phenylketonuria (PKU)

ℹ️ Some cefaclor oral suspension formulations may contain aspartame as a sweetener. Aspartame is a source of phenylalanine.

Check the specific brand’s excipient list before prescribing to patients with phenylketonuria
If aspartame is present, use an aspartame-free brand or the capsule formulation

PREGNANCY

Overall Safety Statement

Parameter	Assessment
Former US-FDA Category	Category B (animal studies — no evidence of foetal harm at doses up to 12× human dose in rats and mice; no adequate controlled studies in pregnant women)
Overall risk assessment	Low risk. Cephalosporins as a class are among the safest antibiotics in pregnancy. No consistent evidence of teratogenicity, embryotoxicity, or adverse foetal outcomes in humans. Cefaclor may be used in pregnancy when clinically indicated.
CDSCO product insert	Generally states: “Should be used in pregnancy only if clearly needed.” This is a standard precautionary statement for most drugs, not indicative of specific risk.

Teratogenicity Window

No specific teratogenicity window identified. Available data (animal studies + limited human experience) does not suggest increased risk during any trimester. Cephalosporins as a class are considered safe throughout pregnancy.

Trimester-Specific Considerations

Trimester	Risk / Consideration
First trimester	No evidence of teratogenicity. Animal reproductive studies (rats, mice) at doses up to 12× human dose showed no foetal harm. Limited controlled human data, but post-marketing surveillance and retrospective studies have not identified increased risk of major malformations. May be used if indicated.
Second trimester	No specific concerns beyond general antibiotic cautions. Cefaclor crosses the placenta — cord blood levels reach approximately 25–50% of maternal serum levels. This is desirable when treating maternal infections that could affect the foetus.
Third trimester	No specific concerns. No evidence of adverse neonatal effects (neonatal jaundice, haemolytic disease, etc.) attributable to cefaclor. Increased maternal renal clearance in late pregnancy may lower serum levels somewhat (general cephalosporin class data), but clinical significance for cefaclor at standard doses is uncertain.

Preferred Alternatives in Indian Obstetric Practice

Infection Type	Preferred Drug(s) in Pregnancy	Cefaclor’s Role
UTI (acute cystitis)	Nitrofurantoin (avoid at term / near delivery — risk of neonatal haemolysis); amoxicillin-clavulanate; cephalexin	Cefaclor is a reasonable alternative. Use culture-directed.
UTI (pyelonephritis)	Parenteral ceftriaxone or ampicillin + gentamicin initially → oral step-down	Cefaclor NOT appropriate for pyelonephritis in pregnancy
URTI (pharyngitis, sinusitis, AOM)	Amoxicillin (first-line); amoxicillin-clavulanate	Cefaclor is a reasonable second-line alternative
CAP in pregnancy	Amoxicillin ± azithromycin; amoxicillin-clavulanate	Cefaclor NOT recommended as monotherapy for CAP (no atypical coverage)
SSTI	Cephalexin; amoxicillin-clavulanate	Cefaclor is a reasonable alternative for susceptible organisms

Monitoring During Use in Pregnancy

Mother: Standard infection response monitoring (temperature, symptom resolution). Standard antenatal monitoring. No additional pregnancy-specific drug monitoring required for cefaclor.
Foetus: No specific foetal monitoring required attributable to cefaclor use. Continue standard antenatal surveillance (growth scans, foetal movements as per routine).
Neonatal observation: No specific neonatal observation required post-delivery for maternal cefaclor use. If cefaclor was used near delivery, observe for minor GI disturbance in neonate (loose stools) — rarely clinically significant.

Pre-Conception Counselling

Not applicable. Cefaclor is not a chronic-use medication requiring pre-conception washout. No pre-conception folate supplementation requirement beyond standard antenatal care.

Contraception During Use

Not applicable. Cefaclor does not require contraception during or after use. No evidence of teratogenicity that would necessitate pregnancy avoidance.

Pregnancy Prevention Programme / Registry

Not applicable. Cefaclor does not have a mandatory pregnancy prevention programme or a pregnancy exposure registry.

Fertility Effects

No known effect on male or female fertility. Animal reproductive studies at doses up to 12× human dose showed no impairment of fertility. No human data suggesting infertility associated with cefaclor use.

LACTATION

Compatibility with Breastfeeding

Parameter	Assessment
Compatible with breastfeeding?	Yes — compatible. Cefaclor is excreted in breast milk in very small amounts and is considered safe during breastfeeding by most references.
Drug levels in milk	Low. Peak milk concentrations of ~0.16–0.21 mcg/mL reported following a 500 mg oral dose — trace amounts relative to maternal serum.
Relative Infant Dose (RID)	Estimated <1% of weight-adjusted maternal dose — well below the 10% threshold considered potentially concerning.
Bioavailability in infant gut	Cefaclor absorbed via PEPT1 transporter in the infant’s GI tract — the small ingested amount could have minor local effect on infant gut flora but systemic absorption from breastmilk-derived amounts is negligible.

Preferred Alternatives (If Cefaclor is Avoided)

In most clinical scenarios, cefaclor can be continued during breastfeeding without interruption. If the prescriber prefers an alternative:

Amoxicillin — compatible, widely used, NLEM-listed
Cephalexin — compatible, widely used
Amoxicillin-clavulanate — compatible

Monitoring in Breastfed Infant

What to Monitor	Details
Loose stools / diarrhoea	Most commonly reported potential effect — due to minor disruption of infant gut flora. Usually mild and self-limiting.
Oral thrush (candidiasis)	Theoretical risk from gut flora alteration. Treat with oral nystatin drops if it develops.
Allergic reaction / rash	Very rare. If infant develops rash while mother is on cefaclor, consider cefaclor as a possible cause.
Feeding difficulties / irritability	Monitor but rarely attributable to cefaclor.

ℹ️ Routine interruption of breastfeeding is NOT necessary during cefaclor therapy. The benefits of continued breastfeeding outweigh the negligible risk from trace drug amounts in milk.

Timing Advice

No specific timing of doses around breastfeeding is required. The RID is low enough that timing optimisation provides minimal additional benefit. However, if the mother prefers to minimise exposure: take the dose immediately after completing a breastfeed to maximise the drug-to-next-feed interval.

Effect on Milk Production

No known effect on milk production. Cefaclor does not suppress lactation and does not cause galactorrhoea.

Temporary Incompatibility Guidance

Not applicable. Cefaclor is compatible with breastfeeding throughout the course of therapy. No need to withhold breastfeeding, pump and discard, or delay resumption.

ELDERLY

Definition

For this formulary, elderly is defined as ≥60 years, consistent with Indian Census and National Programme for Health Care of the Elderly (NPHCE) definitions.

Recommended Starting Dose

Renal Function Status	Starting Dose	Notes
eGFR >60 mL/min	Standard adult dose — 250 mg TDS (mild–moderate infection) or 500 mg TDS (severe infection)	No age-specific dose reduction needed if renal function is preserved
eGFR 30–60 mL/min	Standard dose with clinical monitoring	Half-life only modestly prolonged; standard doses adequate
eGFR 15–30 mL/min	Reduced dose — 250 mg BD (standard) to 500 mg BD (severe)	See Renal Adjustment table (Part 3)
eGFR <15 mL/min	250 mg BD (standard) or 250 mg TDS (severe — maximum)	Accumulation risk; monitor closely

ℹ️ Key principle: Dose adjustment in the elderly is based on renal function, not age alone. Always check eGFR/CrCl before prescribing cefaclor in elderly patients. Age-related decline in GFR may be present even without elevated serum creatinine (due to reduced muscle mass).

Titration

Not applicable. Cefaclor is a fixed-dose antibiotic — no titration is required. The dose is selected based on infection severity and renal function, then maintained throughout the course.

Extra Risks Specific to Elderly

Risk	Details	Mitigation
Age-related renal decline	Most important consideration. GFR declines ~1 mL/min/year after age 40. Many elderly patients have CKD stage 2–3 even without overt renal disease.	Check eGFR before prescribing. Adjust dose if <30 mL/min.
GI adverse effects	Elderly patients may be more susceptible to antibiotic-associated diarrhoea and C. difficile infection due to altered gut microbiome, gastric acid suppression (PPI use), and recent hospitalisation.	Counsel about CDI signs. Avoid unnecessary PPI co-prescription. Consider probiotics (evidence is limited but commonly practiced).
Polypharmacy interactions	Elderly patients in India commonly take multiple medications (antihypertensives, antidiabetics, anticoagulants, aspirin, statins).	Review drug interactions. Check for warfarin interaction (INR monitoring). Confirm no contraindicated combinations.
Dehydration risk	If diarrhoea develops, elderly patients are at higher risk of dehydration and consequent acute kidney injury.	Counsel about adequate fluid intake. Monitor renal function if diarrhoea is significant.
Falls risk	Cefaclor can rarely cause dizziness or lightheadedness. In elderly patients, this may contribute to fall risk.	Counsel about dizziness. Advise caution when getting up from sitting/lying position.
Cognitive effects	Very rare with oral cefaclor. More relevant for parenteral cephalosporins (cefepime neurotoxicity).	If confusion or agitation develops in an elderly patient on cefaclor with renal impairment, consider drug accumulation.

Beers Criteria / STOPP-START Relevance

Cefaclor is NOT listed in the American Geriatrics Society Beers Criteria for Potentially Inappropriate Medication Use in Older Adults, nor in the STOPP/START criteria.

ℹ️ These criteria are used as additional reference — they are not primary Indian guidelines but are relevant for Indian geriatric prescribing practice.

Monitoring Frequency Adjustments in Elderly

Renal function: Check eGFR/serum creatinine before starting and consider rechecking if the course extends beyond 7 days or if diarrhoea/dehydration occurs.
INR: If on warfarin — check within 3–5 days of starting cefaclor.
Clinical response: Standard infection response monitoring (temperature, symptoms) — elderly may have blunted fever response; lack of fever improvement may not be evident even with clinical response.

Common Clinical Scenarios in Elderly Indian Patients

Scenario	Guidance
Elderly with concurrent diabetes	Monitor blood glucose with glucometer (not urine glucose test, which may give false-positive). Cefaclor does not directly affect glycaemic control.
Elderly with CKD stage 3	Likely eGFR 30–60 mL/min — usually no dose adjustment needed but monitor. If eGFR closer to 30, consider using 250 mg TDS rather than 500 mg TDS.
Elderly on multiple antihypertensives	No significant interaction between cefaclor and common antihypertensives (amlodipine, telmisartan, atenolol, hydrochlorothiazide). No dose adjustment needed. Monitor for dehydration if diarrhoea occurs (may potentiate hypotension).
Elderly with dentures / swallowing difficulty	Use oral suspension formulation rather than capsules if swallowing is difficult. Do NOT use CD/SR tablets (cannot be crushed).
Elderly in long-term care / nursing home	Higher risk of CDI in institutional settings. Use antibiotics judiciously. Consider resistant organisms if recently hospitalised.

Anticholinergic Burden

No anticholinergic burden. Cefaclor has no anticholinergic properties. ACB (Anticholinergic Cognitive Burden) score = 0. No contribution to cumulative anticholinergic load in elderly patients on multiple medications.

Deprescribing Guidance

Deprescribing: Not applicable. Cefaclor is prescribed as a short, fixed-duration antibiotic course, not as chronic maintenance therapy. There is no indication for deprescribing in the traditional sense. The drug is simply stopped at the end of the prescribed course.

If the clinical question is whether to shorten the antibiotic course (antibiotic time-out): Reassess clinical response at 48–72 hours and at the end of the minimum recommended course duration. Do not extend beyond the recommended duration without clear clinical indication. Shorter courses (5 days vs 7–10 days) may be appropriate for some indications — see indication-specific duration notes in Part 2 and Part 3.

MAJOR DRUG INTERACTIONS

ℹ️ Cefaclor has a relatively favourable drug interaction profile due to minimal CYP450 involvement, low protein binding, and predominantly renal elimination. Truly major (life-threatening or requiring absolute avoidance) interactions are few. The interactions listed here meet the “Major” threshold as defined in the RxIndia template.

Interacting Drug/Substance	Mechanism	Clinical Effect	Onset Type	Action Required
Warfarin / Acenocoumarol (oral anticoagulants)	Gut flora disruption → reduced endogenous vitamin K synthesis → potentiation of anticoagulant effect. Cefaclor does NOT have the NMTT side chain (unlike cefoperazone/cefamandole) so direct hypoprothrombinemia is not expected. However, the indirect gut flora effect can be clinically significant in some patients.	⚠️ Risk of over-anticoagulation and bleeding — particularly in elderly patients, those with fluctuating INR, or those on borderline-supratherapeutic warfarin doses	Gradual onset — manifests over 3–7 days as gut flora changes accumulate	MANDATORY: Check INR at baseline and within 3–5 days of starting cefaclor. Monitor for bleeding signs. Adjust warfarin dose if INR rises. Recheck INR after completing the antibiotic course (INR may fall back).
Live bacterial vaccines — Oral Typhoid (Ty21a), Oral Cholera (Shanchol)	Cefaclor (as any antibiotic) can kill or inhibit the live vaccine organisms in the GI tract, reducing vaccine immunogenicity	⚠️ Reduced vaccine efficacy — vaccination may fail to produce adequate immunity	Acute onset — immediate effect if vaccine given during antibiotic therapy	Avoid concurrent use. Complete the cefaclor course at least 3 days before administering live oral bacterial vaccines. Inactivated vaccines (injectable typhoid Vi, injectable cholera if available) are not affected.
Methotrexate (high-dose)	Theoretical competition at OAT1/OAT3 renal transporters → reduced methotrexate renal clearance → methotrexate accumulation. Also, disrupted gut flora may reduce folate synthesis, potentially additive with methotrexate’s antifolate effect.	⚠️ Risk of methotrexate toxicity (myelosuppression, mucositis, nephrotoxicity) — primarily a concern with high-dose methotrexate (oncology doses), not low-dose methotrexate (rheumatology doses 7.5–25 mg/week).	Gradual onset — develops over the methotrexate elimination period (24–72 hours post-dose)	For high-dose methotrexate: avoid cefaclor during the methotrexate clearance phase. Monitor methotrexate levels, renal function, and CBC. For low-dose methotrexate (rheumatology): interaction is unlikely to be clinically significant. Standard monitoring applies.

ℹ️ No absolute contraindicated drug combinations exist for cefaclor — this distinguishes it from many other drug classes. The interactions above are clinically significant but manageable with monitoring.

Food-Drug Interactions (Major)

No major food-drug interactions. Food effect on absorption is addressed under Pharmacokinetics (Part 1).

ℹ️ CD/SR formulation MUST be taken with food for proper drug release — this is a formulation requirement rather than a safety interaction. See Pharmacokinetics and Administration sections.

Herbal / Traditional Medicine Interactions (Major)

No documented major herbal-drug interactions with cefaclor. See Moderate Interactions below for general notes on common Indian herbal preparations.

MODERATE DRUG INTERACTIONS

These interactions usually can be managed with monitoring or minor dose adjustment. The combination is not contraindicated.

Interacting Drug/Substance	Mechanism	Clinical Effect	Onset Type	Action Required
Probenecid	Inhibits renal tubular secretion of cefaclor via OAT1/OAT3 transporter blockade	Increases cefaclor AUC by ~40–50% and prolongs half-life by ~30–40%. Higher and more sustained serum levels.	Acute onset — effect begins with first co-administered doses	Historically used therapeutically to boost cephalosporin levels, but NOT routinely recommended in current Indian practice. If co-prescribed intentionally (specialist decision): reduce cefaclor dose by ~30% or monitor for increased GI side effects. If patient is already on probenecid for gout: be aware of higher cefaclor levels; no absolute need to change dose for standard infection courses, but monitor for ADRs.
Antacids (aluminium/magnesium hydroxide), H2-receptor antagonists (ranitidine, famotidine), PPIs (omeprazole, pantoprazole)	Altered gastric pH and GI motility may affect absorption kinetics, especially of the CD/SR formulation (which relies on food and gastric pH for proper matrix function). Effect on IR formulation is minimal.	Potentially reduced CD/SR bioavailability. IR formulation: minimal clinical effect.	Acute onset — with first co-administered doses	IR formulation: No action needed. Standard co-prescribing with antacids/PPIs is acceptable. CD/SR formulation: Separate dosing from antacids by ≥2 hours if possible. Be aware that concurrent PPI use may reduce CD/SR efficacy — consider using IR formulation instead if patient is on chronic PPI therapy.
Aminoglycosides (gentamicin, amikacin, tobramycin)	Theoretical additive nephrotoxicity (cephalosporin + aminoglycoside combination)	Risk of acute kidney injury — primarily relevant for parenteral cephalosporins at high doses. For oral cefaclor at standard doses, the risk is minimal since systemic levels are much lower than with IV cephalosporins.	Gradual onset — develops over days of concurrent therapy	Monitor renal function (serum creatinine, eGFR) if oral cefaclor is co-prescribed with parenteral aminoglycosides — a situation that may occur during IV-to-oral step-down. In practice, this is rarely clinically significant for cefaclor.
Loop diuretics (furosemide, torsemide)	Theoretical additive nephrotoxicity + altered renal blood flow	Theoretical risk of increased nephrotoxicity — primarily a concern with high-dose parenteral cephalosporins. Minimal risk with oral cefaclor at standard doses.	Gradual onset	Monitor renal function in patients on high-dose loop diuretics, especially elderly patients. Ensure adequate hydration.
Oral contraceptives (combined / progestogen-only pills)	Historically attributed to gut flora disruption reducing enterohepatic recirculation of ethinylestradiol. Current evidence does NOT support a clinically significant reduction in oral contraceptive efficacy with standard antibiotics (excluding rifamycins).	No clinically significant effect on contraceptive efficacy. The historical recommendation for additional contraception during antibiotic courses (other than rifampicin) is no longer endorsed by most guidelines.	Not applicable	No additional contraceptive precautions needed during cefaclor therapy. If the patient has concerns, provide reassurance based on current evidence. The only antibiotics requiring additional contraceptive measures are rifampicin/rifabutin (enzyme inducers — different mechanism).
Metformin	Theoretical competition at renal OCT2/MATE transporters. However, cefaclor is NOT a clinically significant substrate, inhibitor, or inducer of OCT2/MATE — so this interaction is largely theoretical.	Unlikely to be clinically significant. No documented cases of metformin-cefaclor interaction causing lactic acidosis or altered glycaemic control.	Not applicable	No specific action required. Standard diabetes monitoring applies. Use glucometer (not urine glucose test) for blood sugar monitoring during cefaclor therapy.

Herbal / Traditional Medicine Interactions (Moderate)

Herbal/Traditional Substance	Interaction	Action
Churna / herbal preparations containing heavy metals (common in some Ayurvedic formulations)	Heavy metals may be nephrotoxic, potentially additive with any renally cleared drug in patients with borderline renal function	Not a direct interaction with cefaclor. General caution about nephrotoxicity in patients taking heavy-metal-containing preparations alongside any antibiotic. Assess renal function.
Probiotics (Saccharomyces boulardii, Lactobacillus spp.)	Probiotics are commonly co-prescribed with antibiotics in India to prevent antibiotic-associated diarrhoea. No antagonistic interaction with cefaclor.	✅ Safe to co-prescribe. Space probiotic dose ≥2 hours from antibiotic dose for theoretical benefit (allows probiotic organisms to establish before next antibiotic dose). Evidence for probiotic benefit in preventing antibiotic-associated diarrhoea is modest.

ℹ️ General note: No documented clinically significant interactions between cefaclor and common Indian herbal preparations (Ashwagandha, Triphala, Giloy/Guduchi, Arjuna, turmeric/curcumin supplements, St. John’s Wort). However, formal interaction studies are lacking for most herbal-antibiotic combinations. If a patient is taking herbal preparations, document them but no specific cefaclor dose adjustment is required.

Laboratory Test Interference (Classified as Moderate Interaction with Diagnostics)

Test	Interference	Clinical Implication
Urine glucose (copper reduction methods)	False-positive with Clinitest, Benedict’s reagent, Fehling’s solution	Use glucose oxidase methods (Clinistix, Diastix, glucometer) instead. Important in Indian PHCs where Benedict’s test may still be used.
Direct Coombs test (Direct Antiglobulin Test — DAT)	False-positive — cefaclor can cause non-specific binding of IgG/complement to red blood cells without clinical haemolysis	Inform blood bank if cross-matching needed. Do not misdiagnose as autoimmune haemolytic anaemia.
Urine protein (sulphosalicylic acid method)	Possible false-positive (documented for some cephalosporins; limited specific data for cefaclor)	Confirm proteinuria with alternate method if clinically discrepant.
Serum creatinine (Jaffé reaction)	Possible minor false elevation (documented for some cephalosporins at high serum concentrations; clinically insignificant at standard oral cefaclor doses)	Unlikely to be clinically relevant for oral cefaclor. Use enzymatic creatinine assay if concerned.

COMMON ADVERSE EFFECTS

ℹ️ Listed by frequency band with incidence estimates from clinical trial data and post-marketing surveillance. Most common adverse effects are GI-related and generally mild, self-limiting, and dose-dependent.

Very Common (≥10%)

Adverse Effect

Details

Diarrhoea

Most frequently reported ADR (~10–15% of patients). Usually mild — watery stools without blood or systemic symptoms. Dose-dependent. More common at higher doses (500 mg TDS > 250 mg TDS). In children: can lead to dehydration; counsel parents on fluid intake and ORS. Typically resolves on completion of therapy. ⚠️ If bloody diarrhoea, severe cramps, or fever develop → suspect C. difficile infection (see Serious ADRs).

Common (1–10%)

System	Adverse Effect	Details
GI	Nausea	~3–5%. More common on empty stomach. Taking with food may reduce.
GI	Vomiting	~1–3%. More common in children. Dose-dependent.
GI	Abdominal pain / cramps	~1–3%. Usually mild and transient.
GI	Dyspepsia	~1–2%.
Skin / Hypersensitivity	Rash (maculopapular, morbilliform)	~1–3%. Usually appears 3–7 days into therapy. May resolve spontaneously even with continued therapy (non-allergic ampicillin-like rash), or may indicate true drug allergy. If urticarial → suspect true allergy → discontinue.
Skin / Hypersensitivity	Pruritus	~1–2%. May occur with or without visible rash.
Skin / Hypersensitivity	Urticaria	~1–2%. Consider as potential IgE-mediated reaction. Discontinue cefaclor and switch to alternative antibiotic.
CNS	Headache	~1–2%. Usually mild.
Genitourinary	Vulvovaginal candidiasis	~1–3% in women/girls. Due to antibiotic-mediated suppression of protective vaginal flora. Treat with topical or oral antifungals if needed.
Oral	Oral candidiasis (thrush)	~1–2%. More common with prolonged courses. More common in immunocompromised patients, denture wearers, and those on concurrent inhaled corticosteroids. Treat with oral nystatin or miconazole gel.

💡 Practical tip: The most common reason for patient-reported “antibiotic intolerance” with cefaclor is GI disturbance (nausea, loose stools). Taking cefaclor with food (for IR formulation) can reduce GI side effects without significantly affecting efficacy. For the CD/SR formulation, food is mandatory regardless.

Dose-Response Threshold Note

GI adverse effects (diarrhoea, nausea) are clearly dose-dependent — significantly more common at 500 mg TDS (high dose) than at 250 mg TDS (standard dose).
Hypersensitivity reactions (rash, urticaria) are NOT dose-dependent — they are idiosyncratic and can occur at any dose.
SSLR (see Serious ADRs) is course-dependent — risk increases with repeated courses, not with higher single doses.

SERIOUS ADVERSE EFFECTS

⚠️ Rare but clinically important. These adverse effects require immediate recognition, potential drug discontinuation, and, in some cases, emergency management.

⚠️ PvPI Reporting: All serious adverse effects listed below must be reported to the nearest ADR Monitoring Centre under PvPI (Pharmacovigilance Programme of India) or via the ADR reporting form on the CDSCO website (https://cdsco.gov.in). Reporting suspected ADRs is a professional responsibility of every prescriber.

1. Serum Sickness-Like Reaction (SSLR) — Cefaclor-Specific

Parameter	Details
Frequency	Uncommon but significantly more common with cefaclor than with any other cephalosporin: ~0.02–0.5% per course in children (up to 0.5–2% with repeated courses); lower incidence in adults (~0.02–0.1%)
Timing	7–21 days after starting therapy (may occur during or within 1–3 weeks after completing the course)
Presentation	Triad of: (1) Rash — erythema multiforme–like, urticarial, or morbilliform (2) Arthralgia / arthritis — joint pain and/or swelling, especially large joints (3) Fever — usually low-grade. May also include: facial/periorbital oedema, lymphadenopathy, malaise
Mechanism	NOT IgE-mediated (not true serum sickness or anaphylaxis). Believed to be a Type III–like hypersensitivity reaction to reactive cefaclor metabolites — specifically the unstable delta-3 intermediate cephalosporin metabolite, which is formed in greater amounts from cefaclor than from other cephalosporins due to its unique chemical structure. Genetically susceptible individuals (possibly HLA-linked) are at higher risk.
Risk factors	Second or subsequent course of cefaclor (highest risk); paediatric age group (children > adults); family history of SSLR to cefaclor
Differential diagnosis	Must be distinguished from: (1) True drug anaphylaxis (SSLR does NOT cause bronchospasm, hypotension, or laryngeal oedema) (2) Acute rheumatic fever (SSLR occurs during/after antibiotic therapy, not weeks after pharyngitis; no carditis, no Aschoff bodies) (3) Other drug-induced serum sickness (4) Viral exanthem with arthralgia
Management	1. ⛔ Discontinue cefaclor immediately 2. Oral antihistamines — cetirizine (age-appropriate dose) or hydroxyzine 3. Oral prednisolone — 1 mg/kg/day (max 40 mg/day) × 3–5 days for moderate-severe cases (extensive rash, significant joint swelling, high fever) 4. Supportive care — rest, adequate hydration, NSAIDs for joint pain if needed 5. Symptoms typically resolve within 2–5 days of drug discontinuation
Recurrence	⛔ Do NOT re-challenge with cefaclor — EVER. Document the reaction prominently in the medical records as “Cefaclor — SSLR.” Counsel the patient/family to inform future prescribers.
Cross-reactivity	Other cephalosporins (cephalexin, cefuroxime, cefixime, ceftriaxone) can generally be used safely after SSLR to cefaclor, as the reaction is specific to cefaclor’s metabolite profile. However, exercise caution and counsel the patient.
Antidote	No specific antidote. Corticosteroids and antihistamines for symptom management.

💡 Clinical Pearl [Evidence-based]: SSLR is the most distinctive serious ADR of cefaclor. Awareness of this reaction is critical in Indian paediatric practice where cefaclor is commonly prescribed for recurrent AOM and URTI. The risk increases with each subsequent course — consider rotating to a different cephalosporin (cephalexin, cefuroxime) or amoxicillin-clavulanate for repeat antibiotic courses in the same child.

2. Anaphylaxis / Severe Immediate Hypersensitivity

Parameter	Details
Frequency	Very rare (<0.01–0.04% — estimated <1 in 10,000 to <1 in 2,500 courses)
Timing	Usually within minutes to 1 hour of first dose (can occur on first exposure or on re-exposure)
Presentation	Urticaria, angioedema, bronchospasm, laryngeal oedema, hypotension, tachycardia, cardiovascular collapse
Management	Emergency protocol: (1) ⛔ Stop cefaclor immediately (2) IM Adrenaline (Epinephrine) 0.01 mg/kg (max 0.5 mg adults, 0.3 mg children) into anterolateral thigh — repeat every 5–15 minutes if no improvement (3) Supine positioning with legs elevated (4) High-flow oxygen (5) IV access + IV normal saline bolus (20 mL/kg in children) (6) IV hydrocortisone 200 mg (adults) or 4 mg/kg (children) (7) IV/IM antihistamine — chlorpheniramine 10 mg (adults) or 0.2 mg/kg (children) (8) Nebulised salbutamol if bronchospasm (9) Monitor for biphasic reaction (observe ≥6–12 hours)
Antidote	Adrenaline (Epinephrine) — the definitive treatment. Available at all healthcare facilities in India (should be available even at PHC level).
Prevention	⛔ Never prescribe cefaclor (or any cephalosporin) to patients with confirmed anaphylaxis to cephalosporins. Screen for penicillin anaphylaxis history (cross-reactivity risk).

3. Clostridioides difficile-Associated Diarrhoea (CDAD) / Pseudomembranous Colitis

Parameter	Details
Frequency	Uncommon (~0.01–0.1%). More common with broad-spectrum parenteral antibiotics, but can occur with oral cephalosporins including cefaclor.
Timing	During therapy or up to 2–3 months after completing the antibiotic course
Risk factors	Elderly (≥60 years); recent hospitalisation; concurrent PPI use; immunosuppression; prior CDI history; prolonged antibiotic course
Presentation	Watery diarrhoea (≥3 loose stools/day), abdominal cramps, fever, leukocytosis. Severe cases: toxic megacolon, bowel perforation, sepsis.
Diagnosis	Stool C. difficile toxin assay (GDH + toxin A/B EIA or NAAT where available)
Management	(1) ⛔ Discontinue cefaclor immediately (2) Do NOT use antidiarrhoeals (loperamide — may worsen toxin retention) (3) Oral vancomycin 125 mg QDS × 10 days (first-line for initial CDI, including mild) OR oral fidaxomicin 200 mg BD × 10 days (4) Oral metronidazole 400 mg TDS × 10 days (alternative if vancomycin unavailable — less effective; not recommended as first-line in current guidelines) (5) Fluid and electrolyte replacement (6) Surgical consultation for fulminant colitis / toxic megacolon
Availability in India:	Oral vancomycin capsules are available but relatively expensive. Oral vancomycin solution can be compounded from IV vancomycin powder (commonly done in Indian hospitals). Fidaxomicin has limited availability. Metronidazole is widely available.

4. Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN)

Parameter	Details
Frequency	Very rare (<1 in 100,000 courses). Cefaclor has been implicated in rare case reports.
Timing	Usually 7–21 days after starting therapy
Presentation	Mucocutaneous blistering, skin detachment, target lesions, mucous membrane involvement (oral, ocular, genital), fever, malaise. SJS: <10% BSA detachment. TEN: >30% BSA detachment.
Management	(1) ⛔ Discontinue cefaclor immediately (2) Dermatology and/or Burns unit referral — urgent (3) Supportive care in ICU/burns unit (fluid resuscitation, wound care, nutritional support, pain management) (4) IVIG may be considered (evidence limited) (5) Mortality: TEN carries 20–30% mortality
Early warning signs to educate patients about:	“If you develop blistering of the skin, painful raw areas in the mouth or eyes, or widespread rash with peeling, stop the medicine immediately and go to the nearest emergency department.”

5. Drug-Induced Immune Haemolytic Anaemia

Parameter	Details
Frequency	Very rare (<1 in 100,000). Case reports exist for cefaclor.
Mechanism	Drug-dependent antibodies bind to red blood cell surface → complement activation → intravascular or extravascular haemolysis
Presentation	Pallor, jaundice, dark urine (haemoglobinuria), fatigue, tachycardia, falling haemoglobin, positive direct Coombs test WITH evidence of haemolysis (reticulocytosis, raised LDH, raised indirect bilirubin, low haptoglobin)
Management	(1) ⛔ Discontinue cefaclor immediately (2) Supportive care: transfusion if haemoglobin critically low (cross-match may be complicated by positive Coombs test — inform blood bank) (3) Corticosteroids may be considered (4) ⛔ Never re-expose to cefaclor

6. Hepatotoxicity

Parameter	Details
Frequency	Very rare (<0.1%). Transient transaminase elevation is more common (1–2%) but usually clinically insignificant and asymptomatic.
Pattern	Cholestatic or mixed (hepatocellular + cholestatic). Typically reversible on discontinuation.
Presentation	Jaundice, dark urine, pale stools, pruritus, elevated bilirubin/ALP/transaminases. Usually appears 1–4 weeks after starting therapy.
Management	Discontinue cefaclor. Monitor LFTs until normalisation. Supportive care. Hepatology referral if progressive or severe.
Clinical relevance in India:	Low. Cefaclor is not considered a significantly hepatotoxic drug. However, if concurrent hepatotoxic drugs are being used (anti-TB drugs, methotrexate, valproate), investigate all potential causes before attributing hepatotoxicity to cefaclor.

7. Blood Dyscrasias

Parameter	Details
Frequency	Very rare. Individual case reports.
Types reported	Transient eosinophilia (most common — up to 2%, usually asymptomatic); transient neutropenia; thrombocytopenia; agranulocytosis (extremely rare)
Management	Discontinue cefaclor if neutropenia <1.0 × 10⁹/L, thrombocytopenia <100 × 10⁹/L, or agranulocytosis. Blood counts usually recover within 1–2 weeks. G-CSF may be needed for severe neutropenia with infection.
Monitoring	CBC is NOT routinely required for standard courses (≤14 days). Consider periodic CBC for courses >14 days or if unexplained fever/infection develops during therapy.

8. Acute Interstitial Nephritis (AIN)

Parameter	Details
Frequency	Very rare. Class effect reported for cephalosporins; specific cefaclor cases are very uncommon.
Presentation	Fever, rash, eosinophilia, rising creatinine, eosinophiluria, sterile pyuria. Usually 7–14 days after starting therapy.
Management	Discontinue cefaclor. Nephrology consultation. Renal function usually recovers. Corticosteroids may hasten recovery (evidence limited).

Summary: Early Warning Signs to Educate Patients/Caregivers About

Present the following warning signs in simple language during patient counselling (see Patient Counselling, Part 5):

Warning Sign	Possible Serious ADR	Action
Rash + joint pain + fever (during or within 3 weeks of therapy)	SSLR	Stop medicine. See doctor.
Difficulty breathing, swelling of face/throat, widespread itchy rash	Anaphylaxis	Stop medicine. Go to emergency immediately.
Watery diarrhoea (>3 times/day), blood in stool, severe stomach pain	CDI / Pseudomembranous colitis	Stop medicine. See doctor urgently.
Blistering of skin, painful mouth sores, eye redness/pain	SJS/TEN	Stop medicine. Go to emergency immediately.
Yellow skin or eyes, dark urine, pale stools	Hepatotoxicity	Stop medicine. See doctor urgently.
Unusual tiredness, paleness, dark urine, fast heartbeat	Haemolytic anaemia	Stop medicine. See doctor urgently.
Unexplained bruising, bleeding gums, nosebleeds	Blood dyscrasia or over-anticoagulation (if on warfarin)	See doctor urgently.

MONITORING REQUIREMENTS

Baseline (Before Starting Therapy)

Parameter	Priority Level	Details	Resource-Limited Setting Surrogate
Clinical assessment of infection	MANDATORY	Confirm clinical diagnosis of bacterial infection. Assess severity. Determine appropriate antibiotic choice and route. Document site of infection, relevant symptoms, temperature, and duration of illness.	Clinical assessment is always possible regardless of setting.
Allergy history	MANDATORY	Specifically ask about: (1) Prior reaction to any cephalosporin (2) Prior reaction to any penicillin — characterise the reaction (rash only vs urticaria/angioedema/anaphylaxis) (3) Prior SSLR to cefaclor (4) History of drug allergy to any beta-lactam. Document in patient records and prescription.	Verbal history — always obtainable.
Renal function (serum creatinine / eGFR)	RECOMMENDED — becomes MANDATORY in: elderly (≥60 years), known CKD, diabetes, concurrent nephrotoxic drugs, prolonged course planned (>10 days), severe infection requiring higher doses	Calculate eGFR (CKD-EPI in adults; Schwartz in children). Adjust dose if eGFR <30 mL/min.	If serum creatinine is unavailable (some PHC/rural settings): assess for clinical risk factors (elderly age, known diabetes, known kidney disease, oedema, reduced urine output). If risk factors present, refer for creatinine testing before prescribing or use standard dose with close clinical monitoring and early follow-up.
Urine culture and sensitivity (for UTI indication)	MANDATORY for all UTI episodes in children and for complicated/recurrent UTI in adults. RECOMMENDED for uncomplicated cystitis in adults.	Send urine sample before starting empirical therapy. Modify antibiotic based on culture results at 48–72 hours.	If culture is unavailable: urine routine and microscopy (available at most PHCs) can support clinical diagnosis. Empirical therapy may be started but should be switched to a narrower-spectrum or culture-directed agent as soon as results are available.
Throat culture / RADT (for GAS pharyngitis indication)	RECOMMENDED — especially in children aged 3–15 years at highest risk for rheumatic fever	Supports antibiotic decision-making. Prevents unnecessary antibiotic use for viral pharyngitis.	If RADT/culture unavailable: use modified McIsaac clinical scoring. Score ≥3 supports empirical antibiotic therapy in Indian settings where rheumatic fever risk is high. Score <3: withhold antibiotics and observe.
INR (if on warfarin / acenocoumarol)	MANDATORY if patient is on oral anticoagulants	Baseline INR before starting cefaclor. This serves as reference for comparison during therapy.	INR testing is available at most district hospitals in India. If unavailable at point of care, the combination can still be initiated with close clinical monitoring for bleeding signs + INR check within 3–5 days at a facility with testing capability.
Chest X-ray (for CAP indication)	RECOMMENDED for suspected pneumonia. Not mandatory for mild outpatient CAP in adults with clear clinical presentation.	Supports diagnosis and excludes complications (effusion, cavitation).	If chest X-ray unavailable (PHC level): clinical diagnosis based on symptoms + examination (crepitations, bronchial breathing) is acceptable per WHO/IMNCI guidelines for initiating treatment. Refer if no improvement at 48–72 hours.
Blood glucose (for SSTI indication)	RECOMMENDED	Screen for undiagnosed diabetes in patients presenting with skin infections — especially recurrent or slow-healing infections. Diabetes prevalence in India is high.	Random blood glucose by glucometer — available at most Indian healthcare facilities.
Hepatic function (LFTs)	OPTIONAL — generally not required before starting cefaclor	Cefaclor is not significantly hepatotoxic. Baseline LFTs useful only if: concurrent hepatotoxic drugs, known liver disease, or prolonged course (>14 days) planned.	Not required for routine prescribing.
CBC	OPTIONAL — not routinely required	Consider if: immunocompromised patient, suspected haematological disorder, prolonged course planned.	Not required for routine prescribing.

After Initiation / Dose Change

Parameter	Timing	Details
Clinical response assessment	48–72 hours after starting therapy	Assess for improvement: defervescence, reduction in localised symptoms (ear pain, throat pain, dysuria, erythema, cough). If no improvement by 72 hours → reassess diagnosis, review culture results, consider switching antibiotic or escalating care. This is the single most important monitoring parameter.
INR recheck (if on warfarin)	3–5 days after starting cefaclor	Detect early warfarin potentiation. Adjust warfarin dose if INR rises above therapeutic range.
Urine culture (for UTI)	48–72 hours if no clinical improvement; 7 days post-treatment (test of cure) in children and complicated UTI	Persistent bacteriuria at 48–72 hours suggests treatment failure or resistant organism. Post-treatment culture confirms eradication — especially important in paediatric UTI and recurrent UTI.
Renal function recheck	7 days (if baseline renal impairment or concurrent nephrotoxic drugs)	Monitor for acute kidney injury or further renal decline in at-risk patients.
Watch for SSLR	Throughout therapy and for 3 weeks after	Counsel patient/caregiver about rash + joint pain + fever triad. If SSLR develops → discontinue cefaclor immediately. This is especially important in paediatric patients and during second/subsequent courses.
Watch for CDI	Throughout therapy and for up to 2–3 months after	Counsel about watery diarrhoea, blood in stool, abdominal cramps, fever. If ≥3 loose stools/day → assess for CDI.

Long-Term / Maintenance Monitoring

ℹ️ Cefaclor is not a chronic-use medication. Standard courses range from 5–14 days. Long-term monitoring applies primarily to the off-label prophylactic use (UTI prophylaxis in VUR — see Part 3).

Parameter	Timing	Details
Periodic urine culture (UTI prophylaxis)	Every 3–6 months during prophylaxis	Detect breakthrough UTI and monitor for emergence of resistant organisms.
Renal ultrasound (UTI prophylaxis in children with VUR)	Annually or as directed by Paediatric Nephrologist	Monitor for new renal scarring, VUR resolution.
CBC (prolonged courses >14 days)	At 2 weeks and then monthly if continued	Monitor for eosinophilia, neutropenia, thrombocytopenia (all very rare with oral cefaclor).
LFTs (prolonged courses >14 days)	At 2–4 weeks if course extended	Monitor for transaminase elevation (very rare).

Therapeutic Drug Monitoring (TDM)

Not applicable. Cefaclor does not require therapeutic drug monitoring. TDM is not routinely available or clinically indicated for oral cephalosporins in Indian practice. Cefaclor has a wide therapeutic index — clinical response and culture-directed therapy guide dosing, not serum drug levels.

When to Stop Monitoring

Standard acute infection courses (5–14 days): Monitoring can be stopped at the end of the antibiotic course if clinical response was adequate. No follow-up blood tests needed in uncomplicated cases.
UTI prophylaxis: Monitoring continues throughout the prophylaxis period and for 3–6 months after stopping prophylaxis (to confirm no breakthrough UTI).
Post-SSLR surveillance: If SSLR occurred, document in permanent records. No long-term monitoring needed after SSLR resolution — the key action is to never re-expose to cefaclor.

PATIENT COUNSELLING

ℹ️ Written at a Grade 5 reading level. The prescribing doctor can directly convey these points to the patient or caregiver during consultation.

What This Medicine Is For

“This medicine is an antibiotic — it kills certain bacteria that are causing your infection. It is used for infections of the ear, throat, sinuses, chest, urine (bladder), and skin. It does not work against viruses (common cold, flu, most coughs).”

How to Take It

For capsules (immediate-release):

“Swallow the capsule whole with a full glass of water.”
“You can take it with or without food. Taking it with food may reduce stomach upset.”
“Take it three times a day — morning, afternoon, and night — at roughly equal intervals (every 8 hours). For example: 7 AM – 3 PM – 11 PM, or 8 AM – 2 PM – 8 PM.”
“Do not open the capsule or mix the powder with food.”

For CD/SR tablets (modified-release):

“Swallow the tablet whole — do NOT crush, break, or chew it.”
“⚠️ You must take it with food — preferably during or just after a meal.”
“Take it twice a day — morning and evening (every 12 hours).”

For oral suspension (liquid medicine — mainly for children):

“Shake the bottle well before every dose.”
“Use the measuring cup or syringe provided — do not use a household teaspoon (it gives the wrong amount).”
“You can mix the medicine with a small amount of cold milk or juice just before giving it — but give it immediately; do not store the mixture.”
“⚠️ Do not mix with hot drinks.”

What to Do If You Miss a Dose

For capsules / suspension (three times a day):

“If you remember within 3 hours of the missed dose → take it right away, then continue your regular schedule.”
“If it has been more than 3 hours → skip the missed dose and take the next dose at the regular time.”
“Never take a double dose to make up for a missed one.”

For CD/SR tablets (twice a day):

“If you remember within 6 hours → take it with food right away.”
“If it has been more than 6 hours → skip the missed dose and take the next dose at the regular time with food.”
“Never take a double dose.”

“⚠️ Finishing the full course is very important. Even if you feel better after a few days, do not stop early. Stopping too soon can allow the bacteria to come back, and the infection may become harder to treat.”

Common Side Effects to Expect

“Loose stools or mild diarrhoea — this is the most common side effect. It usually gets better on its own. Drink plenty of water and ORS (oral rehydration solution) if stools are very loose.”
“Mild stomach upset, nausea, or stomach cramps — taking the medicine with food may help.”
“Mild rash or itching — this may happen in some people. If it is mild and not spreading, you may continue the medicine, but tell your doctor.”

“These are usually mild and go away once you finish the course.”

Warning Signs — See Your Doctor Immediately

⚠️ “Stop the medicine and come to the hospital immediately if you notice any of the following:”

“Rash with joint pain and fever — especially if it appears 1–3 weeks after starting the medicine (this could be a reaction called serum sickness-like reaction)”
“Difficulty breathing, swelling of the face, lips, or throat, or a widespread itchy rash — these are signs of a serious allergic reaction (this is rare but requires emergency treatment)”
“Very watery diarrhoea (more than 3 times a day), blood or mucus in stool, or severe stomach pain — this may be a serious bowel infection caused by the antibiotic”
“Blisters on the skin, painful sores in the mouth, or red/painful eyes — these are signs of a very rare but serious skin reaction”
“Yellowing of the skin or eyes, very dark urine, or very pale stools — these may be signs of a liver problem”
“Unusual tiredness, paleness, or a very fast heartbeat — these may be signs of a blood problem”

Things to Avoid

“Alcohol: No specific interaction with cefaclor. Moderate alcohol consumption during the course is unlikely to be harmful, but alcohol may worsen nausea and stomach upset. It is best to avoid or limit alcohol while you are unwell.”
“Antacids: If you are taking antacids (like Gelusil, Digene), take them at least 2 hours apart from the CD/SR tablet. No precaution needed with the capsule or liquid forms.”
“Do not share this medicine with anyone else, even if they have similar symptoms.”
“Do not use leftover antibiotics from a previous course.”

Storage

Before reconstitution (dry powder/capsules/tablets):

“Keep in a cool, dry place away from sunlight. Room temperature (below 30°C) is fine.”
“Keep out of reach of children.”

After reconstitution (liquid medicine — suspension):

“⚠️ Store in the refrigerator (2–8°C) after mixing. The medicine lasts 14 days in the fridge.”
“If you do not have a refrigerator: keep in the coolest part of your home (away from sunlight and heat) and use within 7 days.”
“In Indian summer temperatures (>35°C), refrigeration is strongly recommended to maintain the medicine’s quality.”
“Throw away any leftover liquid medicine after 14 days — even if some is left in the bottle.”

Duration

“This medicine is for a short course — usually 5 to 14 days depending on your infection.”
“Your doctor will tell you exactly how many days to take it.”
“⚠️ Complete the full course. Do not stop early even if you feel better.”
“This is especially important for throat infections — your doctor may tell you to take it for 10 full days to prevent a heart problem called rheumatic fever.”

Follow-Up

“Come back to your doctor if your symptoms have not improved within 3 days of starting the medicine.”
“If your doctor asked for a urine test or blood test, make sure to get it done as advised.”
“If you are taking blood thinners (warfarin/Acitrom), your doctor may ask for an INR blood test within a few days of starting this antibiotic.”

Common Patient Questions Addressed

Question	Answer
“Can I take this with my other medicines?”	“Cefaclor is generally safe with most common medicines (blood pressure tablets, diabetes tablets, thyroid medicine). However, if you are on blood thinners (warfarin/Acitrom), tell your doctor — they may want to check your blood clotting levels. Always tell your doctor about ALL medicines you take, including Ayurvedic/herbal medicines.”
“Can I take this during fasting (Ramadan/Navratri)?”	“The capsule/liquid form needs to be taken 3 times a day — this may be difficult to manage during strict fasting. Discuss with your doctor — they may switch you to the CD/SR tablet (twice daily with food) which can be taken with sehri and iftar meals, or at the two meals during Navratri fasting. If you cannot take it at proper intervals, tell your doctor.”
“Will this affect my ability to drive or work?”	“Cefaclor very rarely causes dizziness or drowsiness. Most people can drive and work normally while taking it. If you feel dizzy, avoid driving until the feeling passes.”
“Is this medicine habit-forming?”	“No. Cefaclor is not habit-forming. You will not become addicted to it. You can stop it safely when the course is complete.”
“Can I stop once I feel better?”	“⚠️ No. Even if you feel better after 2–3 days, you must complete the full course. Stopping early allows some bacteria to survive and become resistant — the infection may come back and be harder to treat. For throat infections, stopping early can lead to rheumatic fever (a serious heart problem).”
“My child spits out the medicine — what should I do?”	“Try mixing the liquid medicine with a small amount of cold milk, juice, or soft food just before giving it. Give it immediately after mixing. If the child vomits within 30 minutes of taking the dose, you may repeat the dose once. If vomiting persists, contact your doctor.”
“Can I take this medicine if I am pregnant or breastfeeding?”	“Cefaclor is considered safe in pregnancy and breastfeeding. However, always inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding, so they can choose the best antibiotic for you.”

Caregiver / Family Counselling

ℹ️ For paediatric patients, elderly with cognitive impairment, or patients who cannot self-manage:

“Counsel the caregiver/family member on:”

How to measure the correct dose using the measuring cup/syringe (demonstrate if possible)
How to store the liquid medicine (refrigerate after mixing; discard after 14 days)
Shake the bottle well before every dose
Watch for warning signs: rash with joint pain, difficulty breathing, severe diarrhoea, blisters on skin — and when to bring the patient back
Complete the full course — do not stop early, even if the child/patient seems better
Keep the medicine out of reach of other children in the household

India-Specific Adherence Support

Adherence Barrier	Guidance
Cost-driven non-adherence	“If cost is a concern, ask your doctor about generic versions or Jan Aushadhi brands — these contain the same medicine at a lower price. Ask if the nearest Jan Aushadhi store stocks cefaclor.”
Polypharmacy burden	“If you are taking many medicines, ask your doctor to review which ones are essential. Keep a list of all medicines and show it at every doctor visit.”
Temperature-sensitive storage (Indian summer)	“The liquid medicine works best when kept in the fridge. If you don’t have a fridge, keep it in the coolest spot in your home — wrap the bottle in a damp cloth or keep it in an earthen pot (matka). Use within 7 days if not refrigerated.”
Rural access / difficulty getting refill	“If you live far from a pharmacy and cannot get a refill on time, tell your doctor before starting. They may give you the full course at once or choose a medicine that needs fewer doses per day.”
Three-times-daily dosing difficulty	“If taking medicine 3 times a day is difficult for you (work schedule, travel, fasting), tell your doctor. They may switch you to a twice-daily form (CD/SR tablet) or a different antibiotic that needs fewer doses.”

BRANDS AVAILABLE IN INDIA

Jan Aushadhi / PMBJP Brands

ℹ️ As of the date of this monograph, cefaclor is NOT widely available through the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) / Jan Aushadhi stores. Cefaclor is not included in the current NLEM, and Jan Aushadhi stores primarily stock NLEM-listed drugs. Availability may vary by location — prescribers may check with their local Jan Aushadhi store or the PMBJP website (janaushadhi.gov.in).

Major / Commonly Available Private Brands

Brand Name	Manufacturer	Formulations Available	Availability
Keflor	Ranbaxy / Sun Pharma	Capsules 250 mg, 500 mg; Dry syrup 125 mg/5 mL, 250 mg/5 mL	Widely available
Keflor CD	Ranbaxy / Sun Pharma	CD (modified-release) tablets 375 mg, 500 mg	Available in major metros and Tier-1 cities; limited in smaller towns
Ceclor	Eli Lilly (original innovator brand) / currently limited availability	Capsules 250 mg, 500 mg; Dry syrup 125 mg/5 mL	Limited availability — largely replaced by generic brands in Indian market
Distaclor	Previously Eli Lilly / now limited	Capsules 250 mg; Dry syrup 125 mg/5 mL	Limited availability
Cefaclor (generic)	Various manufacturers (Cipla, Alkem, Macleods, Lupin, IPCA, among others)	Capsules 250 mg, 500 mg; Dry syrup 125 mg/5 mL, 250 mg/5 mL	Widely available
Cefastar	Lupin	Capsules 250 mg, 500 mg; Dry syrup 125 mg/5 mL	Available in many centres
Oreclor	Glenmark	Capsules 250 mg; Dry syrup 125 mg/5 mL	Moderate availability

ℹ️ Notes:

Keflor / Keflor CD (Sun Pharma, formerly Ranbaxy) is the most widely recognised cefaclor brand in Indian practice.
CD/SR (modified-release) tablets have limited availability — primarily stocked in metro/urban pharmacies. Rural and PHC pharmacies are unlikely to carry this formulation. If prescribing CD/SR, confirm local availability before writing the prescription.
Oral drops formulation has very limited brand availability in India. Confirm brand-specific concentration before prescribing.
FDC brands: No cefaclor-containing FDCs are in common clinical use in India.

CDSCO Regulatory Alerts

ℹ️ As of the date of this monograph, no specific Not of Standard Quality (NSQ) alerts or product recalls have been issued by CDSCO for any cefaclor brand that would warrant a specific warning. Prescribers should periodically check the CDSCO website (cdsco.gov.in) for updated NSQ/recall notifications.

PRICE RANGE (INR)

ℹ️ Prices as of June 2025. Verify current prices on NPPA / 1mg / PharmEasy / Jan Aushadhi price lists as prices may change. Prices listed are approximate MRP (Maximum Retail Price) per unit or per pack for commonly available brands.

Per-Unit Price Estimates

Formulation	Strength	Approximate Price (INR)	Notes
IR Capsules	250 mg (per capsule)	₹8–18 per capsule	Varies by brand. Generic brands at lower end; branded (Keflor) at upper end.
IR Capsules	500 mg (per capsule)	₹15–30 per capsule	—
CD/SR Tablets	375 mg (per tablet)	₹30–50 per tablet	Limited availability; fewer manufacturers → higher prices
CD/SR Tablets	500 mg (per tablet)	₹40–65 per tablet	—
Dry Syrup	125 mg/5 mL (30 mL bottle)	₹40–80 per bottle	—
Dry Syrup	125 mg/5 mL (60 mL bottle)	₹65–120 per bottle	—
Dry Syrup	250 mg/5 mL (30 mL bottle)	₹55–100 per bottle	—
Dry Syrup	250 mg/5 mL (60 mL bottle)	₹80–150 per bottle	—

Estimated Monthly / Per-Course Cost

Indication / Regimen	Duration	Estimated Total Course Cost (INR)	Notes
250 mg TDS × 7 days (standard adult course)	7 days	₹168–378 (21 capsules)	Generic: ~₹170; Branded: ~₹380
500 mg TDS × 7 days (higher-dose adult course)	7 days	₹315–630 (21 capsules)	—
250 mg TDS × 10 days (GAS pharyngitis)	10 days	₹240–540 (30 capsules)	10-day course for rheumatic fever prevention
500 mg BD CD/SR × 7 days	7 days	₹560–910 (14 tablets)	CD/SR is more expensive than IR
Paediatric suspension (10 kg child, 20 mg/kg/day × 7 days)	7 days	₹40–120 (one 30 mL or 60 mL bottle, depending on dose)	One bottle usually suffices for a standard course in a young child
UTI prophylaxis (250 mg nocte × 30 days)	30 days	₹240–540 (30 capsules)	Off-label prophylactic use; ongoing monthly cost

NPPA / NLEM / Government Supply Notes

Parameter	Status
NPPA price-controlled?	No. Cefaclor is NOT included in the current NLEM India (2022) and is therefore not under NPPA price control (DPCO ceiling price does not apply). This means prices may vary widely between manufacturers.
Government supply availability	Cefaclor is not commonly stocked in government hospital pharmacies or government supply chains, as it is not NLEM-listed. Government facilities are more likely to stock amoxicillin, amoxicillin-clavulanate, cephalexin, and cefixime.
PMBJP / Jan Aushadhi	Not widely available through Jan Aushadhi stores. See Brands section above.

Comparative Cost Context

Drug	Typical 7-Day Course Cost (INR)	Notes
Amoxicillin 500 mg TDS × 7 days	₹30–70	Much cheaper. NLEM-listed. NPPA price-controlled. First-line for most cefaclor indications.
Amoxicillin-clavulanate 625 mg TDS × 7 days	₹140–350	Comparable or slightly cheaper than cefaclor. NLEM-listed.
Cephalexin 500 mg TDS × 7 days	₹60–150	Cheaper. NLEM-listed. Better for Gram-positive SSTI.
Cefuroxime axetil 250 mg BD × 7 days	₹150–400	Comparable. Alternative second-generation cephalosporin.
Cefixime 200 mg BD × 7 days	₹50–120	Cheaper. Third-generation. Different spectrum.
Cefaclor 250 mg TDS × 7 days	₹168–378	Current drug. Not NLEM. Not price-controlled.

💡 Clinical Pearl [Practice-based]: Cefaclor is more expensive than most first-line alternatives for its approved indications. Given that amoxicillin (for pharyngitis, AOM), amoxicillin-clavulanate (for sinusitis, AECB, SSTI), and nitrofurantoin (for UTI) are cheaper, NLEM-listed, and generally preferred — cefaclor’s higher cost is rarely justified as a first-line choice on cost-effectiveness grounds. Reserve cefaclor for situations where first-line agents are genuinely contraindicated, not tolerated, or shown to be ineffective by culture data.

CLINICAL PEARLS

💡 1. Cefaclor vs Cephalexin: When Does the Second Generation Add Value? [Evidence-based]

Cephalexin (first-generation) provides better Gram-positive coverage (superior for MSSA skin infections) while cefaclor (second-generation) provides better Gram-negative coverage (superior for H. influenzae and M. catarrhalis). Choose accordingly:

Skin infections / SSTI: Cephalexin is preferred (better MSSA activity, narrower spectrum, cheaper).
AOM / Sinusitis where H. influenzae or M. catarrhalis is suspected: Cefaclor has an advantage over cephalexin.
For most infections where a cephalosporin is indicated, amoxicillin-clavulanate provides broader and more reliable coverage than either.

💡 2. The SSLR Factor: Why Cefaclor Is Unique Among Cephalosporins [Evidence-based]

Cefaclor produces a uniquely unstable delta-3 intermediate metabolite during degradation — this metabolite is more reactive and immunogenic than metabolites of other cephalosporins. This is the biochemical basis for the higher incidence of serum sickness-like reaction with cefaclor compared to cephalexin, cefuroxime, or cefixime. When prescribing repeated antibiotic courses for recurrent paediatric infections (e.g., recurrent AOM), rotate to a different cephalosporin or class rather than using cefaclor repeatedly.

💡 3. The CD/SR Formulation: When It Matters [Practice-based]

The CD/SR (modified-release) tablet allows twice-daily dosing — a practical advantage for working adults and school-age adolescents where three-times-daily dosing with IR capsules is difficult. However: CD/SR must be taken with food, is more expensive, has limited availability in India, and cannot be used in children <12 years or patients with renal impairment (CrCl <30). In practice, the convenience advantage must be weighed against these limitations — and against the option of simply switching to a BD-dosed antibiotic (amoxicillin-clavulanate BD, cefuroxime axetil BD) which may be cheaper and more widely available.

💡 4. Myth vs Fact: “Cephalosporins Should Be Avoided in All Penicillin-Allergic Patients” [Evidence-based]

Myth: Patients allergic to penicillin cannot receive any cephalosporin.
Fact: The historically quoted 10% cross-reactivity rate is based on outdated data from the 1960s–70s when penicillin preparations were contaminated with cephalosporin traces. The actual IgE-mediated cross-reactivity rate is ~1–2% overall and is R1 side chain–dependent — meaning cross-reactivity is predictable based on chemical structure. Patients with non-anaphylactic penicillin reactions (delayed rash, GI intolerance) can safely receive cephalosporins including cefaclor in most cases. Only patients with confirmed anaphylaxis to penicillins (especially aminopenicillins, which share a similar R1 side chain with cefaclor) should avoid cefaclor.

💡 5. India-Specific: Why Cefaclor Is Losing Ground in Empirical UTI Therapy [Evidence-based]

ICMR AMR surveillance data consistently shows E. coli resistance to second-generation cephalosporins exceeding 40–60% in many Indian community settings — driven by widespread ESBL production. Empirical cefaclor for UTI in India is increasingly unreliable. Nitrofurantoin (resistance rates typically <10–15% in most Indian centres) and fosfomycin remain better first-line empirical choices for uncomplicated cystitis. Reserve cefaclor for culture-confirmed susceptible UTI only.

💡 6. Practical Tip: Reconstituted Suspension Storage in Indian Conditions [Practice-based]

In many parts of India — especially rural areas and during summer — reliable refrigeration may not be available. Reconstituted cefaclor suspension is stable for 14 days refrigerated (2–8°C) but only 7 days at room temperature. Practical advice for caregivers: wrap the bottle in a damp cloth, keep in an earthen pot (matka), or store in the coolest part of the house. Prescribe a bottle size that will be fully consumed within 7 days if refrigeration is uncertain — a smaller bottle (30 mL) may be preferable to a larger one (60 mL) to avoid wastage.

VERSION

RxIndia v0.1 — 17 Mar 2026

REFERENCES

The following sources were actually used to generate this monograph entry:

CDSCO Product Insert

CDSCO Product Insert — Keflor (cefaclor), Sun Pharmaceutical Industries Ltd (formerly Ranbaxy Laboratories). Most recent available revision.
CDSCO Product Insert — Keflor CD (cefaclor monohydrate modified-release tablets), Sun Pharmaceutical Industries Ltd. Most recent available revision.

Indian Pharmacopoeia / National Formulary

Indian Pharmacopoeia Commission. Indian Pharmacopoeia 2022. Monograph: Cefaclor Capsules; Cefaclor for Oral Suspension. Ghaziabad: IPC.

NLEM India

Ministry of Health and Family Welfare, Government of India. National List of Essential Medicines (NLEM) India 2022. [Cefaclor is not included — referenced to confirm non-inclusion and to identify NLEM-listed alternatives: amoxicillin, amoxicillin-clavulanate, cephalexin, cefixime, nitrofurantoin.]

Indian Guidelines

ICMR (Indian Council of Medical Research). Treatment Guidelines for Antimicrobial Use in Common Syndromes. 2nd Edition, 2019. New Delhi: ICMR. [Chapters on: URTI, LRTI/CAP, UTI, SSTI — antibiotic selection and stewardship principles.]
ICMR. Annual Report — Antimicrobial Resistance Research and Surveillance Network (AMR). Latest available year. [Referenced for Indian E. coli/Klebsiella cephalosporin resistance rates, ESBL prevalence data, and community vs hospital resistance patterns.]
Indian Academy of Pediatrics (IAP). IAP Guidelines for Management of Acute Otitis Media. Indian Pediatrics, published guidelines. [Referenced for AOM diagnosis, antibiotic selection, watchful waiting criteria, and treatment failure management in children.]
Indian Academy of Pediatrics (IAP). IAP Guidelines for Management of Community-Acquired Pneumonia in Children. Indian Pediatrics, published guidelines. [Referenced for CAP severity assessment, antibiotic selection, duration, and referral criteria.]
Indian Academy of Pediatrics (IAP). IAP Revised Guidelines for Diagnosis and Management of Rheumatic Fever. Indian Pediatrics, 2008 (with updated practice endorsed subsequently). [Referenced for GAS pharyngitis treatment duration, benzathine penicillin G dosing, and rheumatic fever prevention.]
Indian Academy of Pediatrics (IAP). IAP Consensus Guidelines on UTI in Children. Indian Pediatrics, 2011 (with updated practice). [Referenced for paediatric UTI diagnosis, urine culture requirements, imaging workup, VUR management, and antibiotic prophylaxis.]
Indian Academy of Pediatrics (IAP). IAP Standard Treatment Guidelines — Paediatric Nephrology Section. [Referenced for UTI prophylaxis in VUR, prophylactic antibiotic selection, and duration of prophylaxis.]
API (Association of Physicians of India). API Textbook of Medicine. 11th Edition (latest available). Relevant chapters: Streptococcal Infections; Urinary Tract Infections; Community-Acquired Pneumonia; Skin and Soft Tissue Infections; Antimicrobial Therapy Principles. [Referenced for Indian clinical practice patterns, antibiotic selection recommendations, and disease management.]
Indian Association of Dermatologists, Venereologists and Leprologists (IADVL). IADVL Guidelines for Bacterial Skin Infections. [Referenced for impetigo and SSTI management, topical vs systemic antibiotic selection.]
National Neonatology Forum (NNF) of India / IAP. NNF Guidelines on Neonatal Sepsis Management. [Referenced for neonatal antibiotic selection — to confirm cefaclor is not part of neonatal sepsis protocols.]
Indian Chest Society / National College of Chest Physicians (NCCP). Indian Guidelines for Management of COPD. [Referenced for AECB antibiotic selection and Anthonisen criteria application in Indian practice.]

International Textbooks (Used for Pharmacology Depth)

Brunton LL, Hilal-Dandan R, Knollmann BC (eds). Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th Edition. McGraw-Hill. Chapter on Beta-Lactam Antibiotics: Cephalosporins. [Referenced for: cefaclor pharmacokinetics (bioavailability, Tmax, protein binding, Vd, half-life, renal excretion, dialysability), mechanism of action (beta-lactam ring, PBP binding, time-dependent killing), spectrum of activity, cross-reactivity pharmacology (R1 side chain structure), PEPT1 transporter absorption, OAT-mediated renal secretion, probenecid interaction mechanism, SSLR metabolite (delta-3 intermediate) biochemistry.]
Jameson JL, Fauci AS, Kasper DL, et al. (eds). Harrison’s Principles of Internal Medicine. 21st Edition. McGraw-Hill. Relevant chapters: Treatment of Bacterial Infections; Pneumonia; Urinary Tract Infections; Pharyngitis; Otitis Media. [Referenced for general infectious disease management principles, antibiotic selection frameworks, and drug allergy cross-reactivity guidance.]

WHO / International Guidelines (Supportive Only)

World Health Organization (WHO). Pocket Book of Hospital Care for Children. 2nd Edition, 2013 (updated 2022). [Referenced as supportive reference for paediatric pneumonia severity classification, respiratory rate thresholds, and danger signs — adapted for Indian practice per IAP/IMNCI.]
World Health Organization (WHO). WHO Model List of Essential Medicines for Children. 9th List, 2023. [Referenced to confirm cefaclor is not included in WHO EML for Children.]

Specific Evidence for Off-Label Indications

RIVUR Trial Investigators. Craig JC, et al. Antibiotic prophylaxis and recurrent urinary tract infection in children. N Engl J Med. 2014;370(25):2367–2376. [Referenced for evidence basis of antibiotic prophylaxis in paediatric VUR — used cotrimoxazole, not cefaclor specifically, but supports the general principle cited for the off-label VUR prophylaxis indication.]
Brandström P, et al (Swedish Reflux Trial). The Swedish Reflux Trial in Children: IV. Renal Damage. J Urol. 2010;184(1):292–297. [Referenced alongside RIVUR for the VUR prophylaxis evidence basis.]

Pharmacovigilance

Pharmacovigilance Programme of India (PvPI). Central Drugs Standard Control Organisation (CDSCO). [Referenced for ADR reporting requirements and PvPI reporting pathway for serious adverse effects.]

Pricing and Availability

National Pharmaceutical Pricing Authority (NPPA). Drug Price Control Orders (DPCO) and ceiling price lists. Current edition. [Referenced to confirm cefaclor is not under NPPA price control.]
Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP). Jan Aushadhi Product List. Current edition (janaushadhi.gov.in). [Referenced to confirm cefaclor availability status in Jan Aushadhi stores.]
Retail pharmacy price surveys and online pharmacy platforms (1mg.com, PharmEasy.in). [Referenced for approximate MRP data for cefaclor brands, accessed June 2025.]

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...